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Clostridium difficile is a gram-positive, anaerobic, spore-forming bacterium and 
considered the major cause of antibiotic-associated diarrhea in many countries worldwide. 
Clostridium difficile infection (CDI) in humans causes pseudomembranous colitis. Clinical 
signs range from mild diarrhea to potentially toxic megacolon, bowel perforation, peritonitis 
and even death. Naturally occurring C. difficile infection has also been described in several 
non-human species including pigs, horses, primates, rabbits, rats, dogs and cats. The majority 
of cases, both humans and animals, are associated with disequilibrium of commensal 
intestinal microbiota which is often attributed to antibiotic treatments. The pathogenesis of 
CDI is tightly associated with the cellular effects of toxin A and toxin B and the 
immunologic response associated with these toxins. Despite the importance of these toxins, 
the specific role of each toxin on the pathophysiology of disease is not yet completely 
understood.  
Clostridium difficile is one of the major causes of enteric disease in neonate piglets, 
yet risk factors associated with C. difficile infection in piglets are unknown. Furthermore, 
there is a general lack of prevention strategies available for swine medicine. In our first study 
we used snatch farrowed neonatal pigs to investigate the role of different inoculum doses, 
antimicrobial therapy, and piglet-age on the development of disease. Our results indicated 
that C. difficile dosage appears to be an important risk factor for CDI; 10 day-old pigs can 
develop disease associated with C. difficile, and antibiotic administration following 
inoculation is not a major contributor for disease in neonatal piglets. In our second study we 
investigated the use of lactobacillus and a non-toxigenic C. difficile strain (NTCD) as 
probiotics to prevent CDI in piglets.  Our results showed that NTCD reduces the incidence of 
v 
 
CDI in piglets. Toxin levels, mesocolonic edema and histopathologic lesions were reduced 
when compared to positive control piglets.  Usage of Lactobacillus sp. did not reveal any 
clear benefits. Lastly, we developed a gut-loop ligate model in 7 day-old piglets to study the 
pathophysiology of toxin A and B alone or in combination in different segments of small 
intestine and colon. Results demonstrated that the porcine intestinal loop model has the 
potential to become a valuable resource to further investigate the pathophysiology and 
associated-inflammatory response associated with individual toxins within different segments 
of the intestines. Also, there was a synergistic effect when toxins were administered 
simultaneously. Loops treated with toxin A only had slightly higher histologic scores when 




CHAPTER 1.  GENERAL INTRODUCTION 
 
Introduction 
Clostridium difficile is a gram-positive, strictly anaerobic, spore-forming bacillus first 
isolated by Ivan C. Hall and Elisabeth O`Toole at Colombia University in 1935. The 
bacterium was cultured from healthy neonates` stools, and was initially considered part of the 
normal fecal flora (Hall I. C., O`Toole, E. 1935). It was not until the 1970`s when Bartlett 
and others suggested that this bacterium was the cause of antimicrobial associated diarrhea 
(Bartlett J. G. et al., 1977). Since then, C. difficile has become one of the most important 
enteric pathogens and the leading cause of antibiotic associate diarrhea worldwide. Recent 
reports from the Center for Disease Control and Prevention (CDC) showed Clostridium 
difficile infection (CDI) is responsible for approximately 14,000 annual deaths in the Unites 
States and healthcare costs between $436 million to $3.2 billion annually (Dubberke E. R. et 
al., 2008; European Center for Disease Prevention and Control 2013; Gabriel L., Beriot-
Mathiot, A. 2014; O'Brien J. A. et al., 2007).  
Clostridium difficile infection has been described in humans, pigs, horses, non-
humans primates, rabbits, rats, dogs, hamsters and cats (Arroyo L. G. et al., 2005; Debast S. 
B. et al., 2009; Hopman N. E. et al., 2011; Keessen E. C. et al., 2011a; Norman K. N. et al., 
2009). The vast majority of cases are associated with disruption of the intestinal microbiota 
as may be commonly observed with antibiotic treatment or in neonatal animals with 
undeveloped microbiota (Lawley T. D. et al., 2009; Rupnik M. et al., 2009a).    
Exotoxins A and B (TcdA and TcdB, respectively) are considered the major virulence 




et al., 2011; Modi N. et al., 2011; Voth D. E., Ballard, J. D. 2005). Additionally, some strains 
of C. difficile produce an ADP-ribosylating binary toxin; however, the role of this toxin in 
the pathogenesis of disease development has not been elucidated (Davies A. H. et al., 2011). 
Toxin A and B are part of the large clostridia glucosylating toxin family with molecular 
masses of 308 and 250 kDa, respectively. Genes responsible for toxin production are located 
in a 19.6Kb locus, known as C. difficile pathogenic island (PaLoc). Toxins enzymatic 
domains will target Rho GTPases which include Rho, Ras and Cdc42.  These molecules are 
involved in cellular signaling and cytoskeleton regulation and inactivation of these pathways 
eventually leads to cell rounding and death. (Chumbler N. M. et al., 2012; Davies A. H. et 
al., 2011; Dillon S. T. et al., 1995; Jank T., Aktories, K. 2008; Just I. et al., 1994; Keel M. 
K., Songer, J. G. 2007).  
Clostridium difficile is also an important enteric pathogens in pigs during the first 
week-of-life. Songer and others have shown that in C. difficile affected porcine herds, up to 
two-thirds of the litters can be diseased, and within the litter the morbidity can be as high as 
97-100% (Anderson M. A., Songer, J. G. 2008; Songer J. G. 2004). Mortality rates can vary 
significantly; however, mortality as high as 16% have been reported (Anderson M. A., 
Songer, J. G. 2008). Common gross and histologic lesions associated with CDI in piglets 
include mesocolonic edema and purulent ulcerative colitis, respectively.  
Although the awareness of this disease has increased in swine production over the last 
decade, more research is needed to better understand basic principles such as risk factors, 






The overall objective of the studies described herein was to 1) investigate the 
potential risk factors associated with CDI in piglets 2) evaluate preventative alternatives for 
CDI in piglets and 3) develop of a C. difficile in vivo porcine ligated intestinal-loop model to 
investigate the role of toxins A and B in the pathogenesis and immunologic response of 
disease.  
Risk factors, associated with CDI neonate piglets, evaluated in the first study included 






heat-activated Clostridium difficile 
spores) 2) prior antimicrobial therapy with Lincomycin (Lincocin
®
, Pfizer Animal Health, 
New York, NY), Ceftiour (Excede
®
, Pfizer Animal Health, New York, NY), Tylosin 
(Tylan
®
, Elanco Animal Health, Greenfield, IN) and Tulathromycin (Draxxin
®
, Pfizer 
Animal Health, New York, NY) , and 3) piglet age (10 days-old piglets were challenged).   
The second study focused on the evaluation of the use of Lactobacillus sp. and a non-
toxigenic C. difficile strain (NTCD) as probiotic alternatives to prevent the development of 
CDI in piglets. The final study`s objective was to develop a porcine ligated intestinal-loop 
model to investigate the role of toxins A and B and the cytokine-profile associated with C. 
difficile disease in different segments of the small intestine and colon. 
Dissertation Organization 
 This dissertation is prepared in an alternate manuscript format. The dissertation is 
composed of six chapters and includes a general introduction, a literature review, three 
separate scientific manuscripts, and a general conclusion. References cited in the general 
introduction, literature review, and the general conclusion chapters are listed at the end of the 




refereed scientific journals. The Ph.D. candidate, Paulo Arruda is the primary author of the 
manuscripts and is the principal investigator for the experimental work described.  
 The first manuscript describes the investigation of potential risk factors associated 
with the development of C. difficile disease in neonate piglets. This manuscript was 
published in the journal Anaerobe. The second manuscript describes the investigation of 
potential probiotics including non-toxigenic C. difficile and Lactobacillus sp. on the 
prevention of C. difficile disease in neonate piglets. This manuscript was submitted to 
Preventative Veterinary Medicine. The third manuscript describes the development of a 
porcine ligated intestinal-loop model to study the effects of C. difficile toxin A and B on 
different sections of small and large intestines. This manuscript has been submitted to the 
Journal of Comparative Pathology.  
Literature Review 
Historical background 
          Clostridium difficile was first isolated by Ivan C. Hall and Elisabeth O`Toole at 
Colombia University in 1935 from healthy neonates` stools, and was initially considered part 
of the normal fecal flora (Hall I. C., O`Toole, E., 1935). Interestingly, the bacterium was first 
named Bacillus difficilis due to the bacilli morphology and the difficulty associated with the 
isolation and culture of the bacteria; the word difficilis originated from Latin and translates to 
“difficult” in English. First attempts to associate the bacteria with a disease were made in 
1962, at the time however, there was not enough scientific evidence to support the role of C. 
difficile as a primary pathogen (Smith L., King, E., 1962).  
In the 1950’s, coinciding with the beginning of the antibiotic-era, cases of antibiotic-




aureus was believed to be the primary pathogen associated with such cases (Pearce C., 
Dineen, P., 1960). Clostridium difficile was not classified as a pathogen until the late 1970’s 
when a small cohort of patients suffering from AAD was selected based on a common 
history of clindamycin administration. Conventional medical knowledge was challenged 
when bacterial culture from these patients failed to identify any known enteric bacterial 
pathogens. In addition, S. aureus was highly susceptible to clindamycin leading scientists to 
begin questioning the role of S. aureus in these cases (Tedesco F. J. et al., 1974). In 1977, 
Bartlett and others isolated a clindamycin-resistant bacterium from the Clostridium family 
and, through hamster studies, suggested that this bacterium was the cause of AAD (Bartlett J. 
G. et al., 1977). Later in 1977, two other research groups led by Larson and Price, and Rifkin 
et al. identified toxins in feces from affected and non-affected patients (Larson H. E., Price, 
A. B. 1977; Rifkin G. D. et al., 1977). These finding were followed by the isolation of pure 
culture of C. difficile from affected patients and the identification of toxins. In 1978, the role 
of C. difficile was further investigated in naturally occurring cases and through the 
development of animal models (George R. H. et al., 1978; George W. L. et al., 1978). Since 
then, the bacterium has become one of the most important enteric pathogens and the leading 
cause of AAD worldwide.  The bacterium is responsible for approximately 20% to 30% of all 
AAD reports in the United States (Cohen S. H. et al., 2010; Gabriel L., Beriot-Mathiot, A., 
2014). 
Etiology 
Clostridium difficile is an anaerobic gram-positive and spore-forming bacterium. 
Microscopically, the bacterium appears as short to long bacilli measuring approximately 3 to 




incubation, on blood agar plates. Classic colonies are described as flat, opaque to white, non-
hemolytic, and irregular shaped. Colonies often fluoresce under UV light (Wren M., 2010) 
(Figure 1) and have a characteristic smell. Addition of taurochlorate acid is recommended as 
it facilitates sporulation and, therefore, yields improved culture results (Wren M., 2010). 
Treatment of fecal samples with alcohol at concentration of 50% prior to culture helps select 
C. difficile and controls other bacterial growth (Fedorko D. P., Williams, E. C., 1997). A 
selective media, cycloserine cefoxitin fructose egg yolk agar (CCFA) has been developed to 
facilitate the isolation of C. difficile (Bouza E. et al., 2005; Brazier J. S., 1993). 
 
Figure 1. C. difficile colonies often fluorescence under UV light. 
Clostridium difficile infection 
Clostridium difficile infection has been described in diverse species of mammals 
including humans, pigs, horses, non-humans primates, rabbits, rats, domestic dogs, hamsters 
and domestic cats (Arroyo L. G. et al., 2005; Debast S. B. et al., 2009; Hopman N. E. et al., 




gastrointestinal (GI) tract is colonized by high numbers of organisms including bacteria, 
viruses, and protozoans. Studies have shown that there are 10 times more commensal 
bacteria than somatic and stem cells in the human body (Backhed F. et al., 2005; Hooper L. 
V. et al., 2001; Hooper L. V., Gordon, J. I., 2001), an estimated 10
14 
commensal bacterial 
colonies (Ley R. E. et al., 2006). In addition to the significant number of bacteria, the 
diversity of the bacterial population is extraordinary, making the GI tract the most densely 
populated microbial habitat known in biology (Gill S. R. et al., 2006) and suggested by some 
scientists as one of the most complex ecosystems on the planet. A healthy human colon has 
been reported to contain more than 500 species (Artis D., 2008). A recent study investigating 
the pig intestinal microbiota revealed an even more diverse bacteria population composed of 
approximately 800 different species of bacteria (Looft T. et al., 2012). 
The complex and dynamic relationship among this vast and diverse bacteria 
population is highly associated with the development of several different diseases including 
Clostridium difficile infection (CDI). Clostridium difficile is also found within healthy 
individuals, in particular within neonates (Collignon A. et al., 1993; Delmee M., 2001). An 
early study showed that 61% of healthy neonates are colonized (Holst E. et al., 1981); 
however, only a significantly small proportion of them develop disease. Asymptomatic 
carriage by adults has also been described; however the prevalence is lower than neonates 
(Collignon A. et al., 1993; Delmee M., 2001). Disruption of the normal intestinal flora is 
considered the most important risk factor associated with disease. This is best exemplified by 
the fact that the vast majority of CDI cases in humans are associated with antimicrobial 
therapy, making C. difficile one of the most important nosocomial disease in humans 




LaMont, J. T., 2008; McDonald L. C. et al., 2005; Steele J. et al., 2010). The same pattern is 
observed in animals; however, in addition to antimicrobial treatment, poorly developed 
intestinal flora in neonatal animals is also consider a major risk factor (Lawley T. D. et al., 
2009; Rupnik M. et al., 2009b).  
The bacterium is commonly found in the environment including soil, water, 
vegetables (al S. N., Brazier, J. S., 1996), and animals (Songer J. G., 1996). Clostridium 
difficile produces metabolically-dormant spores which play an essential role in bacterial 
survival when environmental conditions are harsh, and is directly associated with 
transmission, epidemiology and the pathogenesis of disease. Clostridium difficile spores are 
highly resistant to oxygen exposure, desiccation, and most common disinfectants, surviving 
for months and likely years in the environment (Wullt M. et al., 2003). The transmission, for 
most species, is mostly fecal-oral and/or from the environment and primarily due to the 
characteristics mentioned previously. Spores can overcome the unhospitable acidic condition 
of the stomach (Nerandzic M. M. et al., 2009) and, once in the large intestines and under 
proper micro-environmental conditions, are able to germinate and colonize.    
Pathogenesis and toxin action  
Numerous virulence factors associated with CDI have been discovered including 
surface proteins and exotoxins, though there is a consensus that exotoxins A and B (TcdA 
and TcdB, respectively) are the major virulence factors associated with disease development 
(Borriello S. P. 1998; Carter G. P. et al., 2010; Davies A. H. et al., 2011; Modi N. et al., 
2011; Voth D. E., Ballard, J. D., 2005). Some strains of C. difficile also produce an ADP-
ribosylating binary toxin, however the role of this toxin on the pathogenesis of disease 




C. difficile strains are not capable of producing toxins and, therefore, considered 
nonpathogenic (Kelly C. P. et al., 1994). 
Toxins A and B have enterotoxic and cytotoxic affects respectively (Taylor N. S. et 
al., 1981). Toxin A also possesses cytotoxic affects but is 100-fold less potent than TcdB 
(Donta S. T. et al., 1982). It was previously thought that TcdA alone was responsible for 
most of the clinical signs and pathology associated with CDI, and TcdB was not toxic to 
animals unless TcdA was administered simultaneously (Lyerly D. M. et al., 1985; Lyras D. 
et al., 2009). Recent studies and the appearance of the 027 ribotype strain (characterization of 




 and highly pathogenic) have 
changed the way we understand the pathogenesis of this disease. Genetically modified strains 
of C. difficile, created through truncation and subsequent inactivation of particular toxin 
genes, have allowed the investigation of specific toxin roles in hamster and tissue culture 
models. Results from these studies showed that TcdB, not TcdA, is essential for disease 
development; furthermore, disruption of TcdB genes significantly reduces the virulence 
phenotype (Lyras D. et al., 2009).   
Toxins A and B are part of the large clostridia glucosylating toxin family with 
molecular masses of 308 and 270 kDa, 2,710 and 2,366 amino acids, respectively, making 
these toxins two of the largest bacterial toxins that have been characterized. The amino acid 
sequences of TcdA and TcdB are 49% identical and 63% to 66% similar. The genes 
responsible for toxin production are located in a 19.6Kb locus, known as C. difficile 
pathogenic island (PaLoc). The genes responsible for regulation of toxin production are also 





Toxin A and B are composed of a multi-domain structure that contain an N-terminal 
domain, a C-binding terminal domain, a cysteine protease domain, and a hydrophobic 
domain (Davies A. H. et al., 2011; Jank T., Aktories, K., 2008). The C-binding terminal 
domain is involved in toxin binding to cell carbohydrate receptors (Chumbler N. M. et al., 
2012; Davies A. H. et al., 2011; Keel M. K., Songer, J. G., 2007); however, the toxin 
segment varies significantly between TcdA and TcdB suggesting that different receptors on 
the cell surface are involved in binding the two toxins (Keel M. K., Songer, J. G., 2007). 
Alpha-galactosyl receptors with a Gal"1-4GlcNAc core were identified as receptors for TcdA 
in brush border surfaces of hamsters (Krivan H. C. et al., 1986) and on human intestinal 
epithelial cells (Tucker K. D., Wilkins, T. D., 1991). A recent study conducted by Keel and 
Songer showed that the α-galactosyl receptors within piglet enterocytes are likely not 
significant for C. difficile toxin binding (Keel M. K., Songer, J. G., 2007). Cellular receptors 
for TcdB have not yet been identified (Voth D. E., Ballard, J. D., 2005).  Lyerly and others 
showed that intact mucosal surfaces are resistant to the effects of TcdB, and prior trauma are 
likely necessary for toxin internalization (Lyerly D. M. et al., 1985). This finding led 
scientists to the hypothesis that the receptor might be on the basolateral side of the cells (Keel 
M. K., Songer, J. G., 2007). Both toxins are internalized via receptor-mediated endocytosis. 
Subsequent to toxin internalization, a decrease in the pH within the endosome compartment 
results in a toxin structural change, exposure of the hydrophobic domains, and pore 
formation which allows the release of the enzymatic domain of the toxin (N-terminal) into 
the cell cytosol. Once within the cytosol of the cell, TcdA and TcdB target Rho GTPases 
which include Rho, Ras and Cdc42.  These molecules are involved in cell signaling and actin 




compromises actin cytoskeleton regulation, eventually leading to cell rounding, detachment 
from basal membrane, and death (Chumbler N. M. et al., 2012; Davies A. H. et al., 2011; 
Dillon S. T. et al., 1995; Jank T., Aktories, K. 2008; Just I. et al., 1994; Keel M. K., Songer, 
J. G., 2007).  
Enterocyte death and damage to the epithelial tight junctions leads to erosions and 
ulcerations, increased permeability, and a concomitant acute inflammatory process primarily 
characterized by a neutrophilic infiltration and variable amounts of fibrin and proteinaceous 
fluid (pseudomembrane colitis).  Pro-inflammatory cytokines such as IL-1β, TNF-α and IL-8 
are up-regulated within affected areas (Fiorentini C. et al., 1998; Kelly C. P., Kyne, L., 2011; 
Mahida Y. R. et al., 1996; Savidge T. C. et al., 2003) and upon exposure to TcdA and prior 
to cytoskeleton damage, there is activation of NF-kB signaling within enterocytes and 
production of cytokines such as IL-8 (He D. et al., 2002). Dan He and others have shown that 
this inflammatory pathway is independent of cytoskeleton damage (He D. et al., 2002).  It 
has also been shown that these toxins are able to induce apoptosis in epithelial cells, T-cells, 
and eosinophils (Fiorentini C. et al., 1998; Mahida Y. R. et al., 1996).     
Clinical signs in humans 
Clostridium difficile infection affects more than 3 million patients per year in the 
United States (Kelly C. P. et al., 1994; McDonald L. C. et al., 2006; Schroeder M. S., 2005; 
Starr J., 2005). The spectrum of disease is highly variable, from asymptomatic to mild self-
limited diarrhea to more severe cases of colitis. Clinical signs in humans are primarily 
gastrointestinal, and typically involve the colon. Signs include differing levels of diarrhea, 
fever, abdominal pain, and dehydration (Starr J., 2005). Complications attributed with 




reported and often associated with drug-resistant strains and fulminant colitis resulting in the 
need for a colectomy.  Death occurs in approximately 3% to 5% of patients (Sailhamer E. A. 
et al., 2009).    
Clostridium difficile animal models 
Clostridium difficile was recognized as a cause of antimicrobial associated diarrhea 
(AAD) in the late 1970`s and animal models to investigate pathophysiology, bacterial 
colonization and ecology, population dynamics, risk factors and potential treatments  have 
been under development  and are still being refined (Best E. L. et al., 2012). Several different 
animals have been used as models to study CDI; some examples include the hamster, mice, 
guinea pig, rat, prairie dogs, quails, rabbits and pigs (Best E. L. et al., 2012; Lawley T. D., 
Young, V. B., 2013).  The first documented hamster model dates back to 1968 (Small J. D. 
1968); and currently, the hamster model is the most common animal model used to study 
CDI. Despite the availability of reagents and a large body of literature regarding this model, 
hamsters are exquisitely sensitive to the toxins’ effects (after antibiotic administration) and 
commonly die within a few days (Best E. L. et al., 2012; Keel M. K., Songer, J. G., 2006). 
The Rapid and uniformly fatal disease (Best E. L. et al., 2012; Keel M. K., Songer, J. G., 
2006; Lyerly D. M. et al., 1985) differs significantly from CDI in humans. Furthermore, the 
rapid progression of disease in this species also poses obstacles when investigating possible 
treatment and/or prevention options. Chen and others (Chen X. et al., 2008) have shown that 
genetically normal mice, when pretreated with a combination of antibiotics, can develop 
disease which in some circumstances leads to death; however; some of the signs appeared to 





The disease occurs naturally in swine. Pigs are moderately sensitive to the effects of 
C. difficile toxins and the severity of clinical signs and histologic lesions is often related to 
piglet-age and challenge dose (Steele J. et al., 2010). Additionally, the marked similarities in 
nature and progression of CDI in pigs to human disease (Best E. L. et al., 2012; Steele J. et 
al., 2010) and the wide range of assays and immunoreagents commercially available make 
the pig model an attractive alternative to study the disease. Currently there are two piglet 
models suitable to study disease. The first model utilizes gnotobiotic piglets, caesarian-
derived and housed inside sterile isolators for the duration of the study (Steele J. et al., 2010). 
The second model developed by Lizer and others (Lizer J. T. et al., 2012) used snatch-farrow 
commercial piglets housed in a biosecurity level-2 laboratory.  
Clostridium difficile infection in neonatal piglets 
The newborn piglet is born with a sterile gastrointestinal (GI) tract, however 
colonization by mixed populations of bacteria occur within hours of birth (Ducluzeau R., 
1983; Mackie R., I et al., 1999; Mackie R. I. et al., 1999). These bacteria are mechanically 
acquired by piglets via oral contact with the dam’s vaginal canal and perineum, exposure to 
the environment, exposure to feces, teat suckling, and skin contact (Mackie R., I et al., 1999; 
Smith H., 1965). Studies investigating the first intestinal colonization of neonatal piglets 
have identified that Lactobacilli sp, Streptococcus sp, Fusobacterium sp, Clostridium 
perfringens sp, and Escherichia coli are among the first organisms to colonize the small 
intestine and colon (Pesti L. 1962; Smith H., Crabb, W., 1961; Wilbur R. et al., 1960).  
Several factors are believed to play a role in the dynamic succession of microorganism 
colonization. Rapid and drastic changes occur within the intestinal environment after a piglet 




shape the environment, and indirectly select for better fit animals. Within the first few 
minutes of life, microbes within the GI tract compete for niches in a process of succession 
that will eventually establish the intestinal flora. This process of colonization is incredibly 
complex, and likely influenced by the dam’s flora, environmental bacterial population, 
antimicrobial usage, source and quantity of nourishment, modulated by acquired immunity 
from the dam (antibodies and immunological molecules in milk), and lastly modulated by 
active immune responses of the piglet (Ducluzeau R., 1983; Mackie R., I et al., 1999).  
Clostridium difficile intestinal colonization occurs within the first hours of life in the 
neonatal pig, and virtually one hundred percent of piglets in some herds are colonized within 
48 h of birth (Hopman N. E. et al., 2011). Despite the high percentage of colonization, not all 
piglets within a litter develop disease. Studies investigating affected herds have shown that 
on average two-thirds of the litters are clinically affected, and within the litter the morbidity 
can reach 97 to 100% (Anderson M. A., Songer, J. G., 2008; Songer J. G., 2004). Mortality 
rates associated with outbreaks of CDI is variable; however, some have reported mortality 
rates as high as 16% (Anderson M. A., Songer, J. G., 2008). Retardation of growth and lower 
weaning weights, approximately 0.5 Kg lighter on average, have been reported in recovered 
piglets (Songer J. G., 2004).  
The prevalence of C. difficile carriage drops dramatically with age. Studies in a 
variety of countries investigating the prevalence of C. difficile in slaughter pigs revealed a 
consistently low prevalence, ranging from as low as 0% to approximately 8% (Baker A. A. et 
al., 2010; Hoffer E. et al., 2010; Keessen E. C. et al., 2011c; Rodriguez C. et al., 2013). 
Geographic locations, seasonality, and methodological differences are likely responsible for 




Weese J. S., 2010). Interestingly, Schneeberg and others have found that some ribotypes such 
as 078, 126 and 413/FLI01 are more likely to be found in pigs older than 2 weeks 
(Schneeberg A. et al., 2012; Schneeberg A. et al., 2013). Similar results have been reported 
in calves where ribotypes 078 and 126 appeared to be able to colonize longer than other 
ribotypes (Zidaric V. et al., 2012). These results suggest that some ribotypes may be better 
adapted to their host species. 
Epidemiologic studies investigating the presence of C. difficile in retailed meat 
showed that the bacteria can be found at low-levels in uncooked pork (Curry S. R. et al., 
2012). Similar results were found when other types of meat such as poultry, beef, veal, sea 
food, fish and vegetables were investigated (Harvey R. B. et al., 2011; Houser B. A. et al., 
2012; Metcalf D. et al., 2010; Metcalf D. et al., 2011; Metcalf D. S. et al., 2010; Rodriguez-
Palacios A. et al., 2007; Weese J. S. et al., 2009; Weese J. S. et al., 2010). 
Lesions associated with disease are primarily concentrated in the large intestine. 
Macroscopic examination of affected animals reveals mesocolonic edema (Figure 2).  
 
Figure 2. Severe mesocolonic edema observed in a 4-day-old piglet challenged with 





Microscopic examination reveals a multifocal to locally extensive ulcerative 
fibrinopurulent colitis. Gnotobiotic pigs have been described as having systemic disease 
resulting in ascites, pleural effusion, hepatic abscesses, renal dysfunction, and acute 
respiratory distress (Steele J. et al., 2010).  The mechanism by which the microorganism 
causes systemic disease is not yet completely understood.  
In contrast to CDI in humans, where old-age is a risk factor, the disease in swine is 
predominately observed within 1-7 day-old piglets (Hopman N. E. et al., 2011; Songer J. G., 
Anderson, M. A., 2006). Neonatal piglets are highly susceptible to C. difficile colonization as 
the intestinal microflora is not fully established. A recent study conducted by Arruda and 
others (Arruda P. H. et al., 2013) demonstrated that 10 days-old piglets are as susceptible as 
neonatal piglets when challenged with a toxigenic strain of C. difficile. In this particular 
study, piglets were kept in a research environment from birth to the day of challenge, and 
therefore may not be colonized by the microbiota present in a typical farm environment. This 
likely played a role on the susceptibility to disease of these older animals.  
Many risk factors are thought to contribute to CDI including: administration of 
antimicrobials, challenge dose, associated toxin-profile, and animal age. Clostridium difficile 
is the major cause of  AAD in humans (Bartlett J. G. 2002; Carter G. P. et al., 2010; Keel M. 
K., Songer, J. G., 2006; Kelly C. P., LaMont, J. T., 2008; McDonald L. C. et al., 2005; Steele 
J. et al., 2010), however in pigs, scientific evidence for the role of antibiotic usage and 
development of disease is lacking (Waters E. H. et al.,1998; Yaeger M. et al.,2002; Yaeger 
M. J. et al., 2007). A recent study investigated the role of antibiotic usage on neonatal piglets 




any statistical association between antimicrobial usage and disease development or severity 
(Arruda P. H. et al., 2013).  
Disease diagnosis in piglets 
There is a significant gap in knowledge regarding CDI diagnosis in animals, and there 
are no official guidelines available for C. difficile diagnosis. The endemic nature and 
ecological characteristics of this bacterium raise significant challenges for diagnosis. For 
instance, simple culture and isolation of the organism should not be used solely as a 
diagnostic test given the organism can be isolate from healthy animals. Commercially 
available molecular diagnostics, such as real time PCR targeting the detection of the TcdB 
gene (Crobach M. J. et al., 2009), should not be used as a sole diagnostic since this test falls 
for the same reason that mere identification of the organism is not sufficient to diagnose 
disease.  
Identification of an age-group risk (1-7 days-old piglets), and systematic examination 
of clinical signs (watery yellow diarrhea) are the first steps to identify potential cases. At 
necropsy, macroscopic examination of the carcass can reveal mild to severe mesocolonic 
edema (Figure 2). However, mesocolonic edema in piglets is not a good predictor of C. 
difficile toxins (Yaeger M. J. et al., 2007). Though this lesion is suggestive of disease, it is 
not pathognomonic of CDI. 
Clinical signs are primarily due to the release of exotoxins, in this case TcdA and 
TcdB. Cell culture cytotoxicity neutralization assays is considered the gold standard for toxin 
detection (Bartlett J. G., 2006); however, this test is time-consuming, taking approximately 
1-2 days, and requires access and expertise with cell culture methods. There are currently 




These tests were developed and extensively evaluated for use in human infections and have 
not been extensively evaluated for use in swine. Studies investigating the sensitivity and 
specificity of two commercial ELISA kits Tox A/B II (Techlab, Blacksburg, VA) and 
Gastro-Tect Clostridium difficile Toxin A+B (Medical Chemical Corp, Torrance, CA) on 
piglet feces revealed a much lower sensitivity and specificity when compared to human 
stools (Keessen E. C. et al., 2011b). Other studies evaluating the use of ELISA assays on 
stools from horses, pigs and dogs showed similar results where sensitivity and specificity 
were significantly lower when compared to human cases (Anderson M. A., Songer, J. G., 
2008; Arroyo L. G. et al., 2007; Chouicha N., Marks, S. L., 2006). Stools and/or colonic 
content from diarrheic piglets are the recommend sample to perform the ELISA assays 
despite lower sensitivity and specificity in comparison to human samples (Keessen E. C. et 
al., 2011b).  
In addition to complexity and flaws in the toxin-detection tests, Yaeger and others 
showed that when additional enteric pathogens were excluded, pigs with toxin-positive 
results were significantly more likely to have normal feces when compared to toxin-negative 
pigs (Yaeger M. J. et al., 2007). The same study showed that a high percent of apparently 
healthy pigs were positive for the toxins. Clostridium difficile toxin ELISA is routinely used 
for C. difficile diagnosis at the Iowa State Diagnostic laboratory. Table below summarizes 
the total number of C. difficile ELISA(s) performed annually at the Iowa State Diagnostic 









Table 1. Total number of Clostridium difficile ELISA tests performed at the ISU-VDL per 
year since 2003 in addition to the total number of positive and negative results.  
 
At necropsy, a longitudinal section including several colonic loops should be placed 
in 10% formalin for histopathologic examination. Microscopic lesions observed are 
characterized by variably neutrophilic infiltration admixed with low to abundant amounts of 
fibrin and cellular and karyorrhectic debris. Inflammatory exudate is often associated with 
multifocal to coalescing areas of erosion and ulceration, also known as volcano-like lesions 
(Figure 4.) (Songer J. G., Uzal, F. A., 2005). Histologic lesions are highly suggestive of 
disease, however not pathognomonic. Yaeger and other have shown that histologic lesions 
such as erosion, ulcerations and a neutrophilic infiltration are good predictor of the presence 























Figure 4. Histopathologic examination of a piglet challenged with toxigenic C. difficile. 
Section of colon: classic volcano-like lesion characterized by a focal ulceration and 
replacement by moderate to abundant amounts of cellular and karyorrhectic debris, 
degenerate neutrophils, and fibrin. Additionally, expanding lamina propria and separating 
crypts are neutrophils and cellular and eosinophilic debris. 
 
At the ISU-VDL a multi-step diagnosis process including the identification of 
potential cases (clinical history), toxin-detecting ELISA assays, and histologic examination is 
recommend to properly diagnose CDI in piglets. Summary of the ISU-VDL diagnosed data 
revealed that approximately 8984 cases of enteric disease in pigs within the first-week-of life 
were diagnosed since 2003 to the present; C. difficile was diagnosed in 501 of the cases.   
Figure below summarizes the major factors associated with C. difficile in piglets including 





Figure 5. Clostridium difficile intestinal colonization occurs within the first hours of life in 
the neonatal pig, and virtually one hundred percent of piglets in some herds are colonized 
within 48 h of birth. Majority of spores are present with environment and a smaller 
percentage within sow`s gastrointestinal tract. Despite the high percentage of neonatal 
colonization, not all piglets within a litter develop disease. Clostridium difficile colonizes the 
colonic epithelium and produces toxins A (TcdA) and B (TcdB). Toxin A binds to receptors 
within the apical border of enterocyte and is internalized via receptor-mediated endocytosis. 
Disruption of tight junctions and cell rounding allows toxin B to bind to lateral base border of 
cells. Toxin A and B are involved in cell signaling and actin cytoskeleton regulation and can 
eventually reach blood vessels within submucosa and in combination with cytokine produced 
by enterocyte death attract neutrophils to affected area. The prevalence of C. difficile carriage 
animals drops dramatically with age. Studies in a variety of countries investigating the 
prevalence of C. difficile in slaughter pigs revealed a consistently low prevalence, ranging 
from as low as 0% to approximately 8%. 
 
Alternatives for prevention of Clostridium difficile infection in neonatal piglets 
In humans, the prevention of C. difficile disease is primarily divided in two major 




secondly decrease the exposure of susceptible patients to the bacteria or spores. Similar 
principles apply to the disease in piglets; however, the disease is primarily observed in 
neonatal piglets likely due to lack of an established intestinal flora. To date, there are no 
commercially available products to prevent and/or treat CDI in piglets. Results from a recent 
study investigating possible risk factors in piglets show that development and severity of 
lesions can be associated with challenge dose, and therefore alternatives to decrease the 
exposure-dose to neonatal piglets might prevent and/or minimize disease (Arruda P. H. et al., 
2013). The process of cleaning and disinfection is particularly complicated due to the fact 
that C. difficile spores are highly resistant to commonly used disinfectants (Wullt M. et al., 
2003).  
The use of immunotherapy is also considered a good strategy to prevent and control 
disease. In 1991, Lyerly and others investigated the use of antibodies from previously 
immunized cows to prevent disease in hamsters challenged with CDI. Results from this study 
revealed that study-hamsters were protected against the effects of the toxins (Lyerly D. M. et 
al., 1991). More studies utilizing different sources of antibodies followed this study, for 
instance, hamsters were protected from lethal challenge with CDI when previously 
administered avian immunoglobulins against TcdA and TcdB (Kink J. A., Williams, J. A., 
1998). Positive results from these studies and others encouraged the further test in humans. 
To date, there were a total of 15 small clinical trials, and results from these trials suggest that 
intravenous administration of antibodies directed against toxins is beneficial to patients 
suffering from CDI (Leung D. Y. et al., 1991; Rebeaud F., Bachmann, M. F., 2012).  Along 
the same lines, researchers investigated the used of equine-originating antitoxins to prevent 




Immunoglobulins were not able to completely prevent disease, but it significantly decreased 
the severity of histologic lesions associated with CDI on neonatal piglets (Ramirez A. et al., 
2014). More studies are necessary to understand the real benefit and the possible logistical 
issues associated with the use of such techniques in modern swine production. 
Disruption of the intestinal flora and/or lack of flora are considered to be the major 
risk factors and restoration is important for the recovery from CDI. Different studies have 
shown that normal GI flora inhibits C. difficile growth and toxin release (Borriello S. P., 
1990; Parkes G. C. et al., 2009). According to the World Health Organization, probiotics are 
“living organisms, which when administrated in adequate amounts, confer a health benefit to 
the host” (Parkes G. C. et al., 2009). Several studies investigating the use of probiotic to treat 
and/or prevent CDI have led to inconclusive and often contradictory results. Common 
probiotics investigated often contain microorganisms such as Lactobacillus species and yeast 
like Saccharmoyces boulardii. In a recent study, neonatal piglets were intragastrically 
administered with a single dose of lactobacillus and non-toxigenic C. difficile isolate 
respectively, and later challenged with a toxigenic isolate. Results from this study revealed 
that the use of non-toxigenic C. difficile as a probiotic reduced the severity of histologic 
lesions associated with CDI and the amount of toxins detected in neonatal piglets. Use of 
Lactobacillus species did not yield any form of protection against challenge, and animals 
were statistically undistinguishable from piglets receiving toxigenic strains of C. difficile 
alone (Arruda et al. 2014, submitted). 
Antibiotic treatment is the most common treatment utilized for CDI in humans. 
Vancomycin and metronidazole are the drugs of choice. Studies evaluating the antimicrobial 




CHAPTER 2.  EFFECT OF AGE, DOSE AND ANTIBIOTIC THERAPY ON THE 
DEVELOPMENT OF CLOSTRIDIUM DIFFICILE INFECTION IN NEONATAL 
PIGLETS 
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Abstract 
Piglet diarrhea is associated with increased pre-weaning mortality, poor growth rates, and 
variation in weight at weaning. Clostridium difficile is a known cause of enteric disease in 
neonatal piglets, yet risk factors associated with C. difficile infection in piglets are unknown. 
The objectives of this study were (1) to evaluate the consistency and severity of lesions in 
piglets challenged with C. difficile at different bacterial doses (DOSAGE experiment), (2) 
evaluate the use of antibiotics as a contributing risk factor in 1-day-old piglets 
(ANTIMICROBIAL experiment), and (3) to provide a clinical and histological evaluation of 
C. difficile infection in 10-day-old piglets (AGE experiment). One hundred and eleven 
conventional neonatal pigs were snatch farrowed and divided into experimental groups 
addressing the objectives. In the DOSAGE experiment, 40 1-day-old piglets were sham 
inoculated or challenged with varying amounts of C. difficile heat shocked spores and 
euthanized 72 h post infection. Results indicate a clear trend for disease development as 
bacterial numbers increase. In the ANTIMICROBIAL experiment, 39 1-day-old piglets were 
challenged and then treated with one of four different antibiotics after 16 h.  No significant 
difference in disease development was found. Thirty-three 10-day-old piglets were given 




10 day-old piglets. Combined results indicate that C. difficile dosage appears to be an 
important factor that influences the appearance and severity of lesions, 10 day-old pigs can 
develop disease associated with Clostridium difficile, and antibiotic administration following 
inoculation may not be a major contributor for disease in neonatal piglets. 
Introduction 
 Clostridium difficile is a Gram positive, anaerobic, spore-forming bacterium first 
described as part of the neonatal intestinal flora in 1935 [1]. Subsequently, in 1978, 
Clostridium difficile was linked to human colitis [2], and is now a significant cause of 
antibiotic-associated diarrhea in several countries worldwide [3-8]. Clostridium difficile 
infection (CDI) in humans is characterized by mild to severe diarrhea, pseudomembranous 
colitis, and, in the most severe cases, by paralytic ileus, toxic megacolon, bowel perforation, 
peritonitis, and death. CDI has also been described in several non-human species including 
pigs, horses, primates, rabbits, rats, domestic dogs and domestic cats [1,9-12]; disease is 
typically life-threatening only in horses. 
The incidence of CDI has been steadily increasing in veterinary medicine. The 
majority of cases are associated with disequilibrium of commensal intestinal flora. Neonates, 
as well as animals treated with select antimicrobials, are most commonly affected [13,14], 
and the hypothesis of causation is that antimicrobials eliminate susceptible microflora within 
the intestine, thereby allowing strains of C. difficile to establish in empty niches and 
overgrow due to lack of competition.  
CDI in piglets is associated with large bowel inflammation, with the potential for 
pseudomembrane formation. Gnotobiotic pigs have been described as also having systemic 




respiratory distress [8].  The mechanism by which the microorganism causes systemic 
disease is not completely understood. Toxin A (TcdA), toxin B (TcdB), and binary toxin 
(CDT) are known products of many strains of C. difficile. TcdA and TcdB are large 
polypeptides, which are believed to be essential virulence factors associated with disease 
development [1,15].  TcdA is known for enterotoxicity while TcdB is a potent cytotoxin and 
enterotoxin in vivo [5]. There are reports of failed disease associated with TcdB in vivo 
unless prior cellular damage by TcdA has occurred [5,16]. The significance and accuracy of 





 strains. A mouse study demonstrated that TcdB is several times more toxic than 
TcdA and C. difficile isolates lacking TcdA are still capable of causing severe disease [17]. 
These results contradict the theory that TcdA action on tissues is an essential prerequisite to 
cell damage by TcdB. This is further supported by a more recent study using TcdA or TcdB 
gene knock out C. difficile strains.  Reported results from this study indicate both are able to 
cause cellular alterations in vitro and in vivo disease in hamsters, highlighting the fact that 
both toxins are independently capable of producing disease [18].     
Clostridium difficile intestinal colonization occurs within the first hours of life in the 
neonatal pig, and nearly one hundred percent of piglets in some herds are colonized within 48 
h of birth [11]. In contrast to colonization, CDI does not affect all piglets within a litter, but 
can manifest as mild to severe diarrhea in 1-7 day-old piglets [11,19].   Neonatal piglets are 
highly susceptible to colonization, as the intestinal microflora is not fully established. This 
establishes piglets as a good model for human studies but also presents a serious problem in 




Many risk factors are thought to contribute to CDI, including administration of 
antimicrobials, dose, associated toxin profile, and animal age. However, there is a lack of 
knowledge regarding these aforementioned risk factors in swine. The objectives of this study 
were (1) to evaluate the consistency and severity of lesions in piglets challenged with 
different bacterial doses, (2) to evaluate the use of antimicrobials as a contributing risk factor 
in the development of disease, and (3) to provide a clinical and histological evaluation of C. 
difficile infection in 10-day-old piglets.  
Material and Methods 
Animals 
 One hundred and eleven conventional neonatal pigs were procured from a 2,500 head 
sow farm located in central Iowa. Procedures involving sow preparation, piglet collection and 
care were as previously described [20]. Once piglets have been collected and properly 
processed, colostrum collection and administration was performed as described [20]. Pigs 
were then transported to a BSL-2 animal facility at Iowa State University. Sera from all 
procured neonatal pigs were negative for porcine reproductive and respiratory virus (PRRS) 
nucleic acid by PCR. Serum was analyzed for PRRSV nucleic acids using a licensed real 
time PCR assay (Applied Biosystems, CA, USA). 
Housing 
 Piglets were housed in one of six identical raised plastic tubs partitioned into eight 
individual pens (approximately 0.7 x 0.7 m) with clear solid plastic dividing walls. Piglets 
housing and daily care were as described previously [20] with slight modifications. Prior to 
piglet arrival, rooms and plastic tubs were cleaned with total removal of organic material and 




for a 4 h period to effectively eliminate environmental vegetative cells and spores. All 
challenged pigs were housed in the same room and airspace. Negative control piglets were 
housed separately.  
Experimental Design  
Three separate experiments were completed. Table 1 summarizes the design for all 
three experiments.  Each experiment was a specific objective to be investigated: bacterial 
dosage was evaluated in experiment 1 (DOSAGE), antimicrobial usage and the development 
of disease in experiment 2 (ANTIMICROBIAL), and the effect of piglet age in experiment 3 
(AGE). In each experiment, pigs were randomly allocated into four (DOSAGE and AGE) or 
five (ANTIMICROBIAL) groups using several random number iterations in Microsoft 
Excel®. The experimental protocol was approved by the Iowa State University Institutional 
Animal Care and Use Committee (#9-10-7014-S). In the DOSAGE experiment, three 
different quantities of heat shocked C. difficile spores were inoculated. Group 1 received 







difficile spores, respectively (Table 1). For the ANTIMICROBIAL experiment, all groups 
were challenged with 2x10
6
 heat-shocked Clostridium difficile spores. Sixteen hours 
following C. difficile challenge, groups 6, 7, 8, and 9 were each administered a different 
antibiotic (Table 1). The AGE experiment utilized the same protocol for piglet collection. 







spores (Table 1). Piglets were euthanized 72 h after challenge in all experiments. 
Inoculum  
C. difficile isolate ISU-15454-1, was used for all experiments.  This isolate originated 









clinically affected piglets. Isolate 15454-1 is ribotype 078, toxinotype V, and contains both 
toxin A and toxin B gene sequences [21]. The isolate was stored at -80
o
C until culture 
preparation. Procedures involving C. difficile isolation, growth harvesting, and titration of 
spores was accomplished as previously described [20].  
Inoculation 
 All piglets were inoculated intragastrically using an eight-gauge rubber French 
catheter as an oral-gastric tube (Sovereign 
TM
, Tyco/Healthcare, Mansfield, MA). Inoculation 
occurred approximately four h after birth in the DOSAGE and ANTIMICROBIAL 
experiments, and 10 days for the AGE experiment. The negative control groups in the 
DOSAGE and AGE experiments were given 1.25 ml of sterile nanopure water, and then 
flushed with 20 ml of milk replacement. For all inoculated groups in the DOSAGE, 
ANTIMICORBIAL, and AGE experiments, 1.25 ml of challenge preparation containing 
heat-shocked Clostridium difficile spores [20] was given followed by 20 ml of milk 
replacement.  
Antimicrobials   
Sixteen hours post-inoculation, select groups in the ANTIMICROBIAL experiment 
(Table 1) were injected intra-muscularly with one of four antibiotics commonly used in the 
swine industry. The subsequent antibiotics were used: Lincomycin (Lincocin
®
, Pfizer Animal 
Health, New York, NY), Ceftiour (Excede
®
, Pfizer Animal Health, New York, NY), Tylosin 
(Tylan
®
, Elanco Animal Health, Greenfield, IN) and Tulathromycin (Draxxin
®
, Pfizer 





Piglets from all experiments were monitored for 72 h post-challenge and then 
euthanized by an intravenous overdose of pentobarbital.  Gross observations at necropsy 
included 1) body condition, 2) dehydration status, 3) perineal fecal staining, 5) consistency of 
colonic contents, 6) mesocolonic edema, and the presence of 7) visible gross colonic luminal 
necrosis and were scored independently in a blinded fashion as previously described [20,22].  
Necropsies, clinical sign scores and gross lesion scores were completed by the same two 
individuals for all experiments (PHEA and DMM). 
Sample collection 
Immediately prior to inoculation rectal swabs were taken from all pigs. At necropsy, 
fresh and formalin-fixed tissues were collected with flamed instruments soaked in 70% 
alcohol and included ileum, jejunum, descending colon, cecum, and a cross section of spiral 
colon containing 4-5 loops. Colonic and cecal contents were collected in a sterile plastic cup. 
A luminal swab (Dacron
®
 Fiber Tipped, Fisher brand®, Leicestershire, UK) of the ileum was 
also taken. 
Toxin detection and culture 
 Rectal swabs collected prior to inoculation and pooled colon and cecum contents 
retrieved at necropsy were assayed for C. difficile toxins with a commercially available toxin 
ELISA kit (C. DIFFICILE TOX A/B II
TM
, Blacksburg, VA) used according to manufacturer 
instructions and analyzed on a microplate reader (IDEXX Corp, Molecular Device, Lake 
Forest, IL) to semi-quantitatively grade the amount of toxin from 0 (no toxin detection) to 4+ 
(marked toxin detection) as indicated by the manufacturer.  Toxin ELISA was performed 




Pre-inoculation rectal swabs, and post-euthanasia pooled colonic and cecal contents 
were cultured on Clostridium difficile selective agar, both directly and following a 30 minute 
room temperature incubation in 0.5 ml absolute ethanol [20].  All plates were incubated at 
37°C for 48 h in an anaerobic chamber.  C. difficile growth following incubation was semi-
quantitatively scored in a blinded manner by a veterinary microbiologist as follows: 0 = no 
growth, 1 = few colonies, 2 = low numbers of colonies, 3 = moderate growth and 4= high 
growth [20]. Luminal swabs collected at necropsy from the small intestine were examined by 
routine aerobic and anaerobic culture methods for Salmonella spp, Escherichia coli, and 
Clostridium perfringens.  Genotyping for E. coli, and C. perfringens were performed [23,24] 
to determine surface antigen and associated toxin genes.   
Histopathology 
Tissue sections were collected in 10% neutral buffered formalin and allowed to fix 
for 24h. Tissues were then placed in 70% ethanol until routine tissue sectioning followed by 
paraffin embedding and staining with hematoxylin and eosin. Large intestinal sections were 
assessed for goblet cell loss, neutrophilic aggregates within the lamina propria, and mucosal 
epithelial defects as previously described [20]. 
Scoring 
Three categories of scores were compared: 1) clinical signs, 2) gross lesions, and 3) 
microscopic lesions. The scoring system was as previously described [20].Clinical sign 
scores were created by summing scores for body condition, hydration status, and perineum 
staining which ranged from 0 (normal) to three (severe) for each category. Gross lesion 
scores were created by summing scores for necrotizing lesions, mesocolonic edema, culture 




all histopathology categories. Briefly, large intestinal segments were microscopically 
assessed for goblet cell loss, the quantity of infiltrating neutrophils within the lamina propria, 
mucosal alterations, and mesenteric inflammation. Each microscopic category was scored 0 
(normal) to three (severe) depending on severity as previously described [20].  
Statistical methods 
Scores for clinical signs and gross and microscopic lesions were analyzed by a non-
parametric test. Wilcoxon/Kruskal test was used to determine if differences existed between 





statistical software was used to perform analyses. 
Results 
Clinical signs 
 Clinical scores were independently scored for all pigs within their respective groups 
and experiments. Results are summarized in Table 2. Statistical evaluation of clinical signs 
scores from DOSAGE, ANTIMICROBIAL, and AGE experiments revealed no statistical 
difference (p>0.05) among their respective groups. The majority of pigs at necropsy in the 
DOSAGE experiment presented with normal body condition as well as hydration status with 
exception of one animal challenged at 2x10
6
, which presented with moderate levels of 
dehydration. Forty percent (4/10) of piglets challenged at 2 x10
3
 C. difficile spores, 50% 
(5/10) of 2x10
6
, and 80% (8/10) of 2x10
9
 presented with staining of perineum at necropsy. 
Thirty percent (3/10) of control pigs also had mild staining. 
In the ANTIMICROBIAL experiment, most piglets were mildly to severely 




staining of the perineum (38/39, 97.4%).  All but one or two piglets in each group (33/39, 
84.6%) were noted to be thin or emaciated. 
Piglets from all groups in the AGE experiment were of normal body condition, 
hydration status, and had no perineal fecal staining 72 h post inoculation with few 
exceptions. One (1/7, 14.3%) piglet in group 10 was thin and two (2/9, 22.2%) piglets in 
group 13 had fecal staining of the perineum.     
Gross lesions 
Statistical differences were not detected between groups of the DOSAGE, 
ANTIMICROBIAL, and AGE experiments. Grossly visible mucosal necrosis was not seen 
within the cecum or spiral colon of individual piglets in all experiments. Gross lesions by 
experiment are summarized in Table 3. The gross lesions score for the DOSAGE experiment 
were not statistically different between groups. However, the score of group 1 was 
numerically lower than groups 2, 3, and 4. No mesocolonic edema was reported in group 1. 
Mesocolonic edema presented in 30% (3/10) of group 2 piglets and 40% (4/10) of piglets in 
groups 3 and 4.    
Within the ANTIMICROBIAL experiment, mesocolonic edema was reported at 
different frequencies among all groups. Edema was observed in one (1/8, 12.5%) pig each 
from groups 5, 6, and 8. Two (2/8, 25%) piglets in group 7 and four (4/7, 57.1%) from group 
9 had mesocolonic edema 72 h post inoculation.   
Five (5/7, 71.4%) piglets in group 10 of the AGE experiment developed mild 
mesocolonic edema. In group 11, four (4/8, 50%) piglets had edema. Three (3/9, 33.3%) and 





Microscopic lesions  
Classical microscopic lesions with high numbers of neutrophils infiltrating the lamina 
propria, loss of goblet cells and the presence of single to multiple sites of erosions and/or 
ulcerations were observed in sections of colon and cecum from C. difficile challenged piglets 
in the DOSAGE, ANTIMICROBIAL, and AGE experiments.  Observed microscopic lesions 
for all experiments are detailed in Table 4. Significant differences between groups were not 
observed in the DOSAGE, ANTIMICROBIAL, and AGE experiments.  
For the DOSAGE study, overall microscopic lesions scores were not statistically 
different between groups (p=0.2), however, there is a clear numeric trend between dose of C. 
difficile and associated microscopic lesions (Figure 1). Lesion severity was elevated in 
animals challenged at higher doses when compared to lower doses and negative piglets. Only 
rare aggregates of neutrophils were seen within the group 1 piglets. No goblet cell loss or 
mucosal alterations were apparent.  Small intestinal bacterial adherence suggestive of 
Escherichia coli was not observed in any pig from all experiments. 
Toxin ELISA 
 Prior to C. difficile inoculation, rectal swabs from all pigs in the DOSAGE 
ANTIMICROBIAL, and AGE experiments were negative for both toxins A and/or B. Toxin 
ELISA at termination of experiments is summarized in Table 5. 
All the group 1 piglets in the DOSAGE experiment remained toxin negative. Fifty percent 
(5/10) of group 2 piglets were toxin positive at necropsy. Moderate to high levels of toxin 
were detected in four of the five (80%) piglets. Similarly, 50% (5/10) of group 3 piglets were 




Alternatively, 90% (9/10) of group 4 piglets were toxin positive 72 h following inoculation. 
All positive pigs in group 4 had moderate to high levels, (3 or 4+), of toxin present.  
Toxin levels were not detected in any group 6 (0/8) piglet from the 
ANTIMICROBIAL experiment. Low to moderate levels of toxin were detected in three (3/8, 
37.5%) group 7 piglets. Two (2/8, 25%) group 8 and one (1/7, 14.3%) group 9 piglet had low 
amounts of C. difficile toxin present at 72 h post inoculation.  Within the positive control 
piglets, group 5, one (1/8, 12.5%) piglet was toxin positive. However, contrary to other 
groups, toxin was detected at high levels (Table 5). 
In the AGE experiment, no (0/7, 0%) group 10 piglets were positive for C. difficile 
toxin at necropsy. Toxin was detected in three (3/8, 37.5%) group 11 piglets. Two (2/9, 
22.2%) piglets from group 12 and 13 had detectable toxin.  
Bacterial Culture 
Clostridium difficile culture results for the DOSAGE, ANTIMICROBIAL, and AGE 
experiments are summarized in Table 6.  No Salmonella spp was isolated from any pig.  
Twelve C. perfringens isolates were randomly selected for PCR, and all were determined to 
be type A.  Genes associated with Beta 2 toxin were found in three (3/12, 25%) isolates; all 
others were negative. Twelve hemolytic and non-hemolytic E. coli isolates were randomly 
selected and were all negative for pilus antigen and associated toxin genes. 
Discussion 
 Several studies have reported that neonatal piglets are susceptible to C. difficile toxin 
which results in yellow pasty diarrhea [8,25,26]. Pre-weaning mortality, poor growth rates 
and variation in piglet weight at weaning are common problems associated with CDI [27]. 




decade, more research is needed to better understand basic principles such as prevention, risk 
factors, epidemiology and treatment. The treatment of affected animals is occasionally 
complicated by the fact that this bacterium is resistant to different classes of antibiotics [28]. 
A better understanding of the risk factors or triggers is very important in order to effectively 
block or minimize the occurrence of the disease because there is a lack of commercial 
preventive products for CDI.  
Microscopic results of the DOSAGE experiment suggest amplified CDI prevalence 
and severity with increasing exposure dose. It was believed that C. difficile shed by sows in 
farrowing crates was the main route of exposure for neonatal pigs. Although, a recent study 
reported that only about 25% of sows tested were actively shedding the organisms during 
lactation [12]. Studies investigating the source of C. difficile have concluded that neonatal 
pigs, ambient air, and the environment are the major sources of piglet exposure [11,29]. C. 
difficile spores are highly resistant to physical and chemical agents such as farm cleaning 
procedures and most common disinfectants [30,31] and can survive for many months in the 
environment [32]. Therefore, we hypothesize that decreasing the exposure dose to piglets in 
the first day of life and allowing colonization of other microbiome species could have a 
significant impact in disease occurrence as well as disease severity. 
Clostridium difficile is the major cause of antibiotic-associated diarrhea in humans [3-
8] and the same phenomenon is observed in veterinary medicine, where the majority of cases 
are associated with disequilibrium of common intestinal microflora, due to antibiotic 
treatment or young age of animals [33]. A recent study done in mice reported that the use of 
antimicrobials is a critical element in order to cause disease and histopathologic lesions [34]. 




[22,35,36], but confirmation is lacking. In the current study, microscopic lesions associated 
with CDI were observed in piglets enrolled in the ANTIBIOTIC experiment; however, no 
statistical difference was demonstrated between groups. This finding suggests that antibiotic 
treatment, as applied, does not play an important role in the development of and/or in the 
severity of CDI lesions in piglets.  
One day-old piglets do not have an established intestinal microflora, and therefore 
antibiotics would not significantly alter the microflora. This is a potential reason for 
antibiotic therapy not influencing disease severity in the current study. Another debate is that 
the isolate used in this study was susceptible to used antimicrobials reducing the influence of 
treatment. A considerable percentage of piglets involved in this experiment were toxin 
negative and culture negative at the end of the experiment (Table 5). The antibiotic resistance 
profile of C. difficile strains associated with human disease is constantly investigated [37,38]; 
however, studies investigating the resistance profile of piglet C. difficile isolates are lacking. 
A different, susceptible C. difficile isolates could potentially enhance disease severity. Piglets 
treated with antibiotics did, however, have more clinical diarrhea than expected, but a 
reasonable conclusion could not be drawn for this finding. Nonetheless, we believe that a 
better understanding of the role played by antimicrobials in the dynamic of microorganism 
colonization, succession, and competition in the first day of life could contribute to the 
knowledge of neonatal intestinal diseases and the establishment of a healthy microflora. 
There is consensus in the literature that a large majority of cases of CDI in piglets 
occur within the first five days of life [25]. In the AGE experiment, CDI was induced in 10-
day old piglets, indicating susceptibility. The results from this experiment suggest that the 




it does in one day-old piglets. However, these data should be interpreted with caution since 
piglets were kept in a controlled environment until they reached 10 days of age. This perhaps 
limited, and potentially altered, the normal colonization of gut flora which would typically 
have occurred in piglets raised in the farm environment.  Another factor that differentiates 
experimental piglets from piglets raised on farm is milk and its rich source of antibodies. 
These antibodies are responsible for mucosal protection and possibly play a role in bacterial 
colonization and growth. Unexpectedly, the total microscopic score was relatively high in the 
control group. A single piglet in this group had significant microscopic lesions, accounting 
for more than half of the total score of the group. However, this was toxin negative and was 
C. difficile culture negative at the end of the study. Therefore we suspect that microscopic 
lesions are likely not due to C. difficile infection although possible cause of lesions could not 
be determined at this point.   
TcdA and TcdB are believed to be the main factors in disease development [15,39]. 
Toxin ELISA test was performed on piglet feces with the objective of quantifying the toxin 
levels. We were not able to demonstrate a correlation between ELISA results and 
microscopic lesions, and these results were consistent across the three different experiments. 
The effects of C. difficile toxins on enterocytes has been well described[1,5], therefore we 
hypothesize that this failure of correlation might be due to the lack of sensitivity of the 
ELISA used in this study [39]. Furthermore, ELISAs commonly used in veterinary medicine 
were primarily designed to human cases; therefore, any difference which might exist between 
piglet and human cases could potential influence the results. 
Recently, several articles have investigated the use of ELISA as a diagnostic tool for 




due to the wide range in sensitivity and specificity as well as poor positive predictive value 
[40,41]. The ELISA test used in the study identifies the total amount of toxin A and B within 
sample; the test is not capable to differentiating which particular toxin is present within the 
sample. Therefore, it is not possible to extrapolate the role a particular toxin played on 
disease development or the prevalence of toxins within studied animals. As a way to improve 
CDI diagnosis, hospitals are introducing multiple testing algorithms which use ELISA 
associated with other tests such as PCR (targeting genes responsible for toxin production) 
and the glutamate dehydrogenase assay, with the objective of increasing sensitivity and 
specificity. 
In swine medicine, ELISAs are still the most widely used diagnostic tools and are 
frequently the only diagnostic tool used. The lack of correlation in our results, as well as the 
poor sensitivity performance in human medicine, we believe that new CDI diagnostics, such 
as immunohistochemistry and molecular assays, are needed in veterinary diagnostic 
laboratories. Based on the results from these studies, clinical evaluation of piglets is not a 
good measure to evaluate disease development or severity; microscopic lesions appear to be 
the most appropriate method to evaluate such parameters. 
The C. difficile model used for these experiments is predictable and repeatable [20]; 
however, there are multiple limitations. Piglet procurement was from a commercial sow 
farm, and although multiple precautions were taken, all piglets were potentially infected with 
endemic microorganisms [20]. This was important for these experiments as the dynamic of 
microorganism succession and competition is believed to be the key factor for disease 
development. The farm had no previous history of CDI in piglets, but few control piglets 




piglets start to become colonized within a few hours post-farrowing, and within 48 h of life 
100% of farm-raised piglets are colonized [11].  All C. difficile isolates from control pigs 
were toxin negative throughout the study period. Cesarean-surgery piglet derivement would 
limit this potential hazard in future repetitions of the model. Additionally, the large normal 
variation in measured variables, the short study period and the small numbers of piglets per 
group might have contributed to the lack of statistically significant findings of this study. 
In conclusion, the results demonstrate that our isolate can cause microscopic lesions 
and the challenge dose appears to be an important factor that influences the development and 
severity of lesions. In this study, antimicrobial administration appeared to not influence the 
appearance and severity of lesions. It was also demonstrated that 10 day-old-piglets are 
susceptible to the developmental of CDI under these study circumstances. More studies are 
needed to better understand risk factors, epidemiology, and the contribution of antimicrobial 
treatment to the prevalence and severity of C. difficile disease in piglets.  
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Tables and Figures 
Table1. Experimental design. 








2 10 2 x10^3 C. difficile spores 
3 10 2 x 10^6 C. difficile spores 




2 x 10^6 C. difficile spores None 
6 8 2 x 10^6 C. difficile spores Lincomycin 
7 8 2 x 10^6 C. difficile spores Ceftiofur 
8 8 2 x 10^6 C. difficile spores Tylosin 







11 8 2 x10^3 C. difficile spores 
12 9 2 x 10^6 C. difficile spores 
13 9 2 x 10^9 C. difficile spores 
ǂ Heat-shocked Clostridium difficile spores  
* Antibiotic doses were administered per label based on weight and given as directed intramuscularly 












Table 2. Clinical signs by experiment and group. Clinical signs scores included body condition, hydration status, and perineal fecal 
staining at 72 h post inoculation with sham or heat shocked Clostridium difficile spores. 
Clinical signs  
 Body Condition Hydration Status Perineum Staining Sum of scores 
Experiment Group n Range Mean (+/- SE) Range Mean (+/- SE) Range Mean (+/- SE) Mean 
DOSAGE 
1 10 0-1 0.2 (0.13) 0-1 0.3(0.15) 0-1 0.3(0.15) 1.8 
2 10 0 0 (0) 0-1 0.3(0.15) 0-2 0.7(0.3) 1.0 
3 10 0-1 0.2 (0.13) 0-2 0.6(0.22) 0-2 0.7(0.26) 1.5 
4 10 0-1 0.2 (0.13) 0-1 0.4(0.16) 0-2 1(0.21) 1.6 
ANTIMICROBIAL 
5 8 0-2 1.1(0.22) 0-3 1.7(0.36) 1-3 2.2(0.36) 5.1 
6 8 0-2 1.5(0.32) 0-3 1.8(0.44) 1-3 2.6(0.26) 6 
7 8 0-2 1.5(0.26) 1-3 2(0.37) 0-3 2.1(0.39) 5.6 
8 7 0-2 1.14(0.26) 1-3 2(0.3) 1-3 2.5(0.29) 5.8 
9 8 0-2 1.2(0.25) 1-3 2.1(0.64) 2-3 2.6(0.18) 6 
AGE 
10 7 0 0(0) 0(0) 0 0 0(0) 0 
11 8 0 0(0) 0 0(0) 0 0(0) 0 
12 9 0 0(0) 0 0(0) 0 0(0) 0 











 Mesocolonic Edema Culture Toxin Sum of scores 
Experiment Group n Range Mean (+/- SE) Range Mean (+/- SE) Range Mean (+/- SE) Mean 
DOSAGE 
1 10 0 0(0) 0-2 1.1(0.27) 0 0(0) 1.1 
2 10 0-3 0.5(0.3) 0-3 1.3(0.33) 0-4 1.7(0.59) 3.5 
3 10 0-3 0.8(0.35) 0-3 0.4(0.3) 0-4 1.3(0.49) 2.5 
4 10 0-3 1(0.44) 0-3 2.4(0.3) 0-4 3(0.36) 6.4 
ANTIMICROBIAL 
5 8 0-3 0.37(0.37) 0-2 1.2(0.25) 0-4 0.5(0.5) 2.1 
6 8 0-2 0.25(0.25) 0-1 0.12(0.12) 0 0(0) 0.3 
7 8 0-3 0.5(0.37) 0-2 1(0.32) 0-2 0.6(0.32) 2.1 
8 7 0-1 0.14(0.14) 0-1 0.5(0.2) 0-1 0.28(0.18) 0.9 
9 8 0-1 0.5(0.18) 0-2 0.3(0.26) 0-1 0.12(0.12) 1 
AGE 
10 7 0-1 0.71(0.18) 0-1 0.5(0.2) 0 0(0) 1.3 
11 8 0-3 0.87(0.39) 0-3 1.8(0.39) 0-2 0.5(0.26) 3.3 
12 9 0-2 0.44(0.24) 0-4 2.3(0.37) 0-3 0.4(0.33) 3.2 






Table 4. Microscopic lesions 72 h post inoculation in large intestine of piglets sham challenged or challenged with heat shocked 
Clostridium difficile spores by experiment and group.  
 





Goblet cell loss 
Neutrophilic 
inflammation 




Group n Range Mean (+/- SE) Range Mean (+/- SE) Range Mean (+/- SE) Range Mean (+/- SE) 
Mean 
DOSAGE 
1 10 0 0(0) 0-2 0.7(0.26) 0 0(0) 0 0(0) 0.8 
2 10 0-3 0.8(0.41) 0-3 0.7(0.33) 0-3 0.4(0.3) 0-1 0.1((0.1) 2.6 
3 10 0-3 0.9(0.37) 0-3 1.2(0.41) 0-3 0.9(0.4) 0-2 0.4(0.22) 4.7 
4 10 0-3 1.4(0.42) 0-3 1.4(0.42) 0-3 1.2(0.44) 0-2 0.7(0.26) 5.5 
ANTIMICROBIAL 
5 8 0-3 0.75(0.41) 0-3 0.87(0.39) 0-3 0.5(0.37) 0-1 0.25(0.16) 3.8 
6 8 0-3 0.5(0.37) 0-3 0.62(0.41) 0-2 0.25(0.25) 0-1 0.12(0.12) 1.8 
7 8 0-3 0.37(0.37) 0-3 0.5(0.37) 0-3 0.37(0.37) 0-1 0.12(0.12) 3 
8 7 0-2 0.28(0.28) 0-2 0.57(0.29) 0-1 0.14(0.14) 0-1 0.14(0.14) 2.1 
9 8 0-1 0.25(0.16) 0-2 0.5(0.26) 0-1 0.12(0.12) 0 0(0) 1.3 
AGE 
10 7 0-2 0.71(0.36) 0-3 1.14(0.53) 0-3 0.71(0.47) 0-1 0.14(0.14) 4.1 
11 8 0-2 0.25(0.25) 0-3 0.62(0.37) 0-1 0.12(0.12) 0-3 0.5(0.37) 2.8 
12 9 0-1 0.11(0.11) 0-1 0.33(0.16) 0 0(0) 0-3 0.77(0.36) 1.2 




Table 5.  Clostridium difficile culture and toxin ELISA results by experiment from pigs 
challenged with heat shocked Clostridium difficile spores (culture and toxin ELISA were 
performed on pooled large intestinal contents and colonic mucosal scrapings). 




1 2/10 0/10 . 
2 7/10 5/10 . 
3 2/10 5/10 . 
4 9/10 9/10 . 
ANTIMICROBIAL 
5 6/8 7/8 . 
6 0/8 1/8 Lincomycin 
7 3/8 5/8 Ceftiofur 
8 0/7 4/7 Tylocin 
9 1/8 2/8 Tulathromycin 
AGE 
10 4/7 0/7 . 
11 7/8 1/8 . 
12 8/9 3/8 . 
13 7/9 2/9 . 
* Number of samples culture positive for C. difficile per total number of piglets within each 
group. 
† Number of samples toxin positive for C. difficile per total number of piglets within each 
group. 
¶ Only piglets enrolled in the ANTIMICROBIAL experiment were treated; 16 h post 













Table 6. Small intestine culture results by experiment from pigs challenged with heat 












1 0/10 0/10 2/10 . 
2 0/10 3/10 0/10 . 
3 2/10 1/10 0/10 . 
4 1/10 2/10 0/10 . 
ANTIMICROBIAL 
5 2/8 1/8 1/8 . 
6 7/8 1/8 1/8 Lincomycin 
7 5/8 1/8 1/8 Ceftiofur 
8 1/7 1/7 1/7 Tylocin 
9 1/8 1/8 0/8 Tulathromycin 
AGE 
10 3/7 1/7 0/7 . 
11 5/8 4/8 0/8 . 
12 1/8 1/8 0/8 . 
13 4/9 0/9 0/9 . 
* Number of samples culture positive for hemolytic Escherichia coli per total number of 
piglets within each group.  
† Number of samples culture positive for Clostridium perfringens per total number of piglets 
within each group. 
 ‡ Number of samples culture positive for smooth or mucoid Escherichia coli per total 
number of piglets within each group.  
¶ Only piglets enrolled in the ANTIMICROBIAL experiment were treated; 16 h post 











Figure 1. Mean microscopic lesions by group for the DOSAGE experiment. There were no 
significant differences between groups; however, there is a clear trend with increased dose of 




 heat-shocked Clostridium difficile spores 
† 2x106  heat-shocked Clostridium difficile spores 
‡ 2x109  heat-shocked Clostridium difficile spores 




CHAPTER 3.  BACTERIAL PROBIOTICS AS AN AID IN THE CONTROL OF 
CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE IN NEONATAL PIGS 
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Abstract 
  Clostridium difficile infection (CDI) in piglets is associated with large bowel 
inflammation, with the potential for pseudomembrane formation, and can lead to production 
losses or increased mortality. Although CDI is a common disease in the swine industry, there 
is a general lack of prevention strategies. The objectives of this study were to evaluate: (1) 
the usage of Lactobacillus sp. and (2) non-toxigenic C. difficile (NTCD) prevention 
alternatives in the development of CDI in piglets. One hundred and fifty five cesarean 
derived piglets were randomly assigned to six different groups as follows: GROUP 1 
negative control (n= 10), GROUP 2 NTCD only (n= 13) , GROUP 3 Lactobacillus sp. only 
(n= 14), GROUP 4 positive control (challenged with toxigenic C. difficile strain) (n= 35), 
GROUP 5 NTCD and challenged with the toxigenic C. difficile strain  (n= 34), GROUP 6 
Lactobacillus sp. and challenged with the toxigenic C. difficile strain (n= 44). Assigned 
groups according to experimental design received a single dose of selected preventative at 4 
hours-of-life and were challenged with toxigenic C. difficile sixteen hours later. All piglets 
were euthanized at 72 hours post infection.  Results showed a benefit of the usage of NTCD 
to prevent CDI in piglets, the prevalence of toxin-positive piglets, mesocolonic edema and 
histopathologic lesions were reduced when compared to positive control piglets.  Usage of 





 Disease associated with Clostridium difficile, a Gram positive, anaerobic, spore-
forming bacterium, has been described in several species including humans, pigs, horses, 
non-human primates, rabbits, rats, domestic dogs and cats (Arroyo et al., 2005; Debast et al., 
2009; Norman et al., 2009; Hopman et al., 2011; Keessen et al., 2011).  The majority of CDI 
cases are associated with alterations in the gastrointestinal commensal flora, as with 
antimicrobial therapy, or with undeveloped flora, as in neonatal animals (Rupnik et al., 2009; 
Lawley et al., 2009). Several studies have shown the role of antimicrobial usage in the 
development of disease in humans, making CDI the leading cause of antibiotic-associated 
diarrhea in several countries worldwide (Bartlett, 2002; McDonald et al., 2005; Keel and 
Songer, 2006; Kelly and LaMont, 2008; Carter et al., 2010; Steele et al., 2010). Discontinued 
use of antimicrobials (Poutanen and Simor, 2004; Keessen et al., 2011) and probiotic 
administration are common measures used to control the disease in humans (Parkes et al., 
2009; Fitzpatrick, 2013).   Alternative techniques to treat disease include the use of fecal 
transplant  (Vaishnavi, 2014) or use of specific bacteria species as probiotics. For instance 
studies using hamster models have shown that colonization with a non-toxigenic strain of C. 
difficile (NTCD) can prevent CDI (Borriello and Barclay, 1985; Seal et al., 1987; Sambol et 
al., 2002). Similar results were achieved when NTCD were administered to two human 
patients suffering from CDI (Seal et al., 1987).  
  Clostridium difficile is one of the most important enteric pathogens in pigs within the 
first week-of-life. Songer and others have shown that within affected herds on average two-
thirds of the litters are affected, and within the litter the morbidity can be as high as 97-100% 




mortality as high as 16% have been reported (Anderson and Songer, 2008). Additionally, 
growth retardation and lower weaning weights in surviving pigs has been reported (Songer, 
2004). The newborn piglet is born with a virtually sterile gastrointestinal tract, but 
colonization by mixed populations of bacteria occurs within hours of birth. Colonizing 
microbes are mechanically acquired by the piglets via oral contact within the dam’s vaginal 
canal, perineum, teats, exposure to feces, and skin contact (Mackie et al., 1999). Several 
factors play a role in the dynamic succession of organisms that make up the microflora. 
During the piglet’s life, several other microbes compete for places in microbial niches 
in a process of succession that eventually establishes the flora, consisting of well over 500 
distinct species of bacteria in the mature gastrointestinal tract (Artis, 2008). Clostridium 
difficile intestinal colonization occurs within the first hours of life in the neonatal pig, and 
nearly one hundred percent of piglets in some commercial herds are colonized within 48 h of 
birth (Hopman et al., 2011). Our research team believes that an intervention during the initial 
colonization period can prevent CDI in piglets.  
Even though CDI is a common disease in the swine industry, there is a lack of sound 
prevention strategies. Therefore, the objectives of this study were to evaluate the use of (1) 
Lactobacillus sp. and (2) a non-toxigenic C. difficile strain (NTCD) as ingested 
microorganism (probiotic) alternatives to prevent the development of CDI in piglets. 
Materials and Methods 
Animals 
Pregnant, second to third parity, cross-bred sows from a commercial herd with no 
history of C. difficile disease were purchased and delivered to Iowa State University (ISU) 




surgeries were performed on sows and the neonatal piglets were manually provided pooled 
colostrum.  All one hundred and fifty-five piglets included in this study were triaged at birth 
with navels clamped, cut, and sprayed with 5% iodine solution (Durvet, MO, USA). Piglets 
also received an iron injection at birth. Piglets were kept in a BSL-2 animal facility for the 
duration of the experiment. 
Sera from all neonatal piglets were negative for porcine reproductive and respiratory 
virus (PRRSV) nucleic acid by PCR. Serum was analyzed for PRRSV nucleic acids using a 
licensed real time PCR assay (Applied Biosystems, CA, USA). 
Housing 
Piglets were individually housed in new 18 gallon plastic totes (Rubbermaid®, Port 
Washington, NY) at a room temperature (29°C); heat lamps were placed above the totes with 
the objective to increase the microenvironmental temperature of piglets to approximately 
35°C. All piglets receiving toxigenic C. difficile were housed in the same room and airspace. 
Negative control, Lactobacillus sp. only and NTCD only piglets were housed in separate 
rooms. Piglet housing and daily care have been described by Arruda et al. (2013). Briefly, 
piglets were fed milk replacer (Esbilac; Pet-Ag, Hampshire, IL) three times daily (7 am, 12 
pm, and 7 pm) by oral-gastric lavage using an 8 French catheter (Sovereign TM, 
Tyco/Healthcare, Mansfield, MA). At feeding time, piglets were monitored for clinical signs 
and side effects; piglet behavior, fecal staining and hydration status were evaluated. 
Experimental Design 
 The study design is summarized in Table 1. Briefly, the study contained six separate 
groups as follows: GROUP 1 negative control (10 piglets), GROUP 2 NTCD only (13 




(challenged with a toxigenic C. difficile strain) (35 piglets), GROUP 5 NTCD and challenged 
with the toxigenic C. difficile strain(34 piglets), GROUP 6 Lactobacillus sp. (Probiotic 
Complex) and challenged with the toxigenic C. difficile strain (44 piglets). Four replicates of 
the study were performed, summing up to 155 piglets. Two different potentially preventative 
treatments were utilized: 1) commercially available Lactobacillus sp. and 2) a NTCD strain. 
In each experiment, pigs were randomly allocated into one of the six groups using several 
random number iterations in Excel® (Microsoft, Redmond, WA). The experimental protocol 
was approved by the ISU Institutional Animal Care and Use Committee, protocol number 10-
12-7445. 
Preventive treatments were administrated intragastrically, according to experimental 
design, approximately four hours after birth. Piglets from GROUPS 2 and 5 received 2x10
6
 
heat-shocked NTCD spores, and piglets from GROUPS 3 and 6 received 2x10
6
 Lactobacillus 
sp. in a yogurt suspension. Sixteen hours following probiotic administration, groups 4, 5, and 
6 were challenged with 2x10
6
 heat-shocked toxigenic C. difficile spores (Table 1). Piglets 
were euthanized 72 h after challenge. 
 
Inoculum 
The toxigenic bacterial isolate (C. difficile isolate ISU-15454-1) utilized for these 
experiments was obtained from a field case of piglet diarrhea received at the ISU Diagnostic 
Laboratory. High levels of toxin (4+) were detected by ELISA (C. DIFFICILE TOX A/B 
IITM, Blacksburg, VA) from the clinically affected piglet. Isolate 15454-1 is ribotype 078, 
toxinotype V, and contains both toxin A and toxin B gene sequences (Rupnik et al., 1998). A 
1.25 ml of solution containing 2 x 10
6




followed by 20 ml of milk replacer.  The isolate was stored in Chopped meat broth at 3-5∘C; 
spores from the isolate were prepared and stored at 3-5∘C prior until experimental use.  
Procedures involving C. difficile isolation, growth and harvest of spores have been previously 
described (Lizer et al., 2013). Furthermore, spore titration and heat shock activation prior to 
challenge have also been previously described (Lizer et al., 2013). 
NTCD 
The non-toxigenic strain was kindly provided by Dr. Songer’s laboratory. Strain JGS 
653 was obtained from a clinically-normal piglet in North Carolina. PCR assays for TcdA 
and TcdB were negative and toxin production was not detected in 7 day dialysis bag cultures 
in brain heart infusion (Songer et al., 2007).  An aliquot (1.25 ml) of solution, containing 2 x 
10
6
 heat-shocked NTCD spores, was administered intragastrically, followed by 20 ml of milk 
replacement. 
Lactobacillus sp. 
The Lactobacillus sp. preparation was prepared as follows: 75 billion CFUs of 
Probiotic Complex (GNC, General Nutrition Corporation, Pittsburg, PA) were used to fortify 
the amount of Lactobacillus acidophilus in yogurt. One capsule containing 75 billion CFUs 
of probiotic was thoroughly mixed with 190 ml of yogurt.  Each piglet was administered 5 ml 
of this fortified yogurt to provide an approximate total amount of 2 x 10
6
 Lactobacillus sp. 
 Inoculation 
Approximately four hours after birth, groups 2, 3, 5, and 6 received either NTCD or 
Lactobacillus sp. intragastrically using an 8 French catheter as an oral-gastric tube 
(Sovereign TM, Tyco/Healthcare, Mansfield, MA). At 20 hours after birth (16 hours post-




containing heat-shocked toxigenic C. difficile spore solution intragastrically as previously 
described (Arruda et al., 2013). 
Necropsy 
 Clinical scores were independently and blindly scored for all pigs at the completion 
of study. Piglets were monitored for 72 h post-challenge and then euthanized by an 
intravenous overdose of pentobarbital.  Gross observations at necropsy included 1) body 
condition (normal, thin, emaciated), 2) hydration status (normal, mild, moderate, severe 
dehydration), 3) perineal fecal staining (none, mild, moderate, severe), 4) consistency of 
colonic contents (-1 = firm/pelleted, 0 = normal, 1 = pudding-like, 2 = watery) , 5) 
mesocolonic edema (mild = 1 mm separation between loops, moderate = 2–3 mm separation 
between loops, severe >3 mm separation between loops), and 6) the presence of visible 
colonic luminal necrosis.  All were scored independently in a blinded fashion as previously 
described (Yaeger et al., 2007; Lizer et al., 2013; Arruda et al., 2013).  Necropsies, clinical 
sign scores and gross lesion scores were completed by the same two individuals for all 
experiments (PHEA and DMM). 
Sample collection 
 Rectal swabs were taken from all pigs prior to inoculation. At necropsy, fresh and 
formalin fixed tissues were collected with instruments disinfected between animal 
necropsies. Samples included:  ileum, jejunum, descending colon, cecum, and a cross section 
of spiral colon containing 4-5 loops. Colonic and cecal contents were collected and stored in 
sterile plastic cups. An ileal swab (Dacron
®
 Fiber Tipped, Fisher brand®, Leicestershire, 





 Rectal swabs collected prior to inoculation and pooled colon and cecal contents (from 
same pig) collected at necropsy were assayed for C. difficile toxins. A commercially 
available toxin ELISA kit (C. DIFFICILE TOX A/B II
TM
, Blacksburg, VA) was used to 
semi-quantitatively measure the amounts of toxin from 0 (no toxin detection) to 4+ (marked 
toxin detection) as indicated by the manufacturer.  Swabs and intestinal pooled content were 
frozen and stored at -80 °C until completion of study. All samples were processed 
simultaneously and in accordance with manufacturer instructions and analyzed on a 
microplate reader (IDEXX Corp, Molecular Device, Lake Forest, IL). 
 Histopathology 
 Tissue sections were collected in 10% neutral buffered formalin. Sections were 
submitted for routine tissue sectioning followed by paraffin embedding and staining with 
hematoxylin and eosin. All tissues were examined by a veterinary pathologist (PHEA) who 
was blinded to animal group designation.  Large intestinal sections were assessed for goblet 
cell loss, neutrophilic aggregates within the lamina propria, and mucosal epithelial defects as 
previously described (Lizer et al., 2013; Arruda et al., 2013). See Table 2 for detailed 
microscopic scores.  
Scoring  
Four categories of scores were compared: 1) clinical signs, 2) ELISA results 3) 
mesocolonic edema, and 4) microscopic lesions. Summing the scores for body condition, 
hydration status, and perineal staining were done to create clinical signs scores. ELISA 
assays were performed on fecal and colon contents at the beginning and end of the 
experiment. At necropsy, pathologists that were blinded to the treatment group and assigned 




histopathology categories. Score system has been previously described (Lizer et al., 2013; 
Arruda et al., 2013). 
Statistical methods 
Scores for clinical signs, gross and microscopic lesions were analyzed by a non-parametric 
test. Kruskal-Wallis test was used to determine if there was an overall difference among 
study groups. Pair-wise comparison was performed using Wilcoxon test; (p) value were then 
adjusted using Bonferroni correction. Correlations between microscopic lesions, mesocolonic 
edema, and ELISA results were accessed by Spearman’s rank correlation coefficient, a non-




statistical software was used to perform analyses. 
Results 
Bacterial Culture 
 C. perfringens and E. coli were isolated from majority of piglets regardless study 
group. Nine isolates were randomly selected for PCR genotype. 100% of C. perfringens 
isolated were determined to be type A.  
No hemolytic E. coli was isolated; PCR genotype was performed on nine randomly selected 
isolates. One isolate was positive for STb toxin gene; however, all were all negative for pilus 
antigen and other associated toxin genes. Salmonella was not isolated from any intestinal 
swab.  
Clinical signs 
 Clinical scores were independently and blindly scored for all pigs at completion of 
the study. Overall statistical evaluation of clinical signs scores from study groups revealed no 




The majority of pigs at necropsy from GROUPS 1, 2 and 3 presented with normal body 
condition as well as hydration status:  90% (9 out of 10 pigs), 85% (11 out of 13 pigs) and 
93% (13out of 14 pigs), respectively. Among Groups receiving the toxigenic isolate 
(GROUPS 4, 5 and 6) normal body condition and hydration status accounted for only 66% 
(23out of 35 pigs), 61% (21out of 34 pigs), 61% (27out of 44 pigs) respectively; although 
this difference was not statistically significant (p>0.05).  Pigs receiving the toxigenic isolate 
(GROUPS 4, 5 and 6) had slightly higher clinical scores when compared to GROUPS 1, 2 
and 3 having mild diarrhea and some degree of dehydration; 23% of pigs receiving the 
toxigenic strain presented some level of dehydration associated with loss in body condition 
while only approximately six percent of pigs from group 1, 2 and 3 showed similar levels of 
dehydration and clinical signs.  
Gross lesions 
GROUP 5 presented significant lower scores when compared to GROUPS 4 and 6 
(p=0.01). Other group comparisons failed to achieve statistical significance. Grossly visible 
mucosal necrosis was not observed within the cecum or spiral colon of individual piglets in 
all experiments. Figure 1 demonstrates the individual data points and median across different 
study groups. 
All animals were fecal toxin ELISA negative at the beginning of the experiment. At 
necropsy (72 hours post inoculation), ELISA results showed that GROUP 5 had lower levels 
of toxin when compared to GROUPS 3, 4 and 6 (Figure 2). Additionally, the prevalence of 
positive samples was markedly different among these groups; toxins were detected in only 
5.8% of pigs (2 out of 34 pigs) from GROUP 5 while toxins were detected in 35.7% (group 





Histopathologic examination revealed classic microscopic large intestinal lesions 
characterized by variable numbers of neutrophils within lamina propria, a loss of goblet cells 
and single to multiple sites of epithelial erosion or ulceration which were occasionally 
covered by moderate amounts of cellular and karyorrhectic debris and fibrin; lesions were 
only observed within colon and cecum (See Figure 3. for Group lesions distribution score). 
Statistical comparison among groups showed that GROUP 4 had higher scores when 
compared to other groups. GROUP 5 presented lower microscopic scores when compared to 
GROUPS 3, 4 and 6; GROUP 5 scores were markedly similar of piglets belonging to 
GROUPS 1 and 2. Although numerical differences were observed, pair comparisons did not 
yield significant results 
Correlations 
Associations among mesocolonic edema, toxin levels and microscopic lesions were 
accessed and results showed that mesocolonic edema, ELISA toxin levels and microscopic 
lesions are highly and significantly correlated among each other with consistent (p) values < 
0.001 on all combinations 
Discussion 
 Clostridium difficile disease is the most important cause of nosocomial diarrhea in 
humans; the disease has become a major healthcare concern as incidence and severity of 
disease have increased significantly over recent years (Kelly and LaMont, 2008; Chumbler et 
al., 2012). Numerous studies have also documented the susceptibility of the neonatal piglet to 
such infection; affected piglets commonly develop watery to pasty yellow diarrhea in the first 




Despite the significant health and economic impact of disease in humans and other species, 
no commercial vaccine is available. Once diagnosed in humans, the disease is commonly 
treated by discontinuing antibiotic use (Poutanen and Simor, 2004; Keessen et al., 2011) and 
administration of probiotic bacteria and treatment with metronidazole or vancomycin (Parkes 
et al., 2009; Fitzpatrick, 2013). Most recently a technique known as fecal transplant is 
gaining acceptance and importance on the treatment of disease in humans (Vaishnavi, 2014).  
Different studies have shown that the normal gastrointestinal flora inhibits C. difficile 
growth and toxin release (Borriello, 1990; Parkes et al., 2009) and, therefore, disruption of 
normal flora is the major risk factor for C. difficile disease development in humans. 
Probiotics are defined by the World Health Organization as “living organisms, which when 
administrated in adequate amounts, confer a health benefit to the host” (Parkes et al., 2009). 
Potential mechanisms of how probiotic benefits the host have been described in different 
studies (Parkes et al., 2009; Fitzpatrick, 2013; Hell et al., 2013). In summary, the most 
important mechanisms include competitive exclusion; bacterial metabolic activity; 
preservation of gut barrier function; influence on water and ion channels; influence of innate 
nervous system; modulation of signal transduction; and stimulation of innate immune system 
and induction of   adaptive immunity (Hell et al., 2013). 
The two types of bacterial probiotics utilized in this study included a non-toxigenic 
strain of C. difficile (NTCD) and a commercially available probiotic composed of 
Lactobacillus sp. Different studies using hamster models have shown that colonization with a 
NTCD can prevent CDI (Borriello and Barclay, 1985; Seal et al., 1987; Sambol et al., 2002). 
Another study, this time involving two human patients with recurrent CDI showed significant 




piglets, in farm settings, exposed to NTCD had lower levels of fecal toxin when compared to 
controls (2007).  To our knowledge this is the first experiment, in controlled settings, 
performed to investigate the benefits of such an alternative in piglets. 
Macroscopic evaluation of colon and cecum wall did not reveal necrotizing lesions; 
this result is consistent with our previous findings where piglets were challenged with 




 spores/ml and necropsied at 72 
hours post inoculation (Arruda et al., 2013).  Mesocolonic edema, although not 
pathognomonic, is still considered the major and often only macroscopic lesion associated 
with clinical cases of CDI in piglets. Results from this study showed that piglets challenged 
with toxigenic C. difficile are more likely to have mesocolonic edema when compared to 
control piglets. This result is in accordance with previous literature (Songer et al., 2000). 
Interestingly, piglets administrated with NTCD then challenged showed significant lower 
rates of mesocolonic edema when compared to positive control challenged piglets and were 
not statistically different from control animals; for instance, mesocolonic edema was 
observed in 54% of pigs from GROUP 4 and only in 17% of pigs from GROUP 5. These 
results indicate a possible benefit of NTCD on the prevention of the development of 
macroscopic lesions associated with CDI.  
Overall, piglets from control groups presented a trend of lower clinical scores when 
compared to challenged groups (GROUPS 4, 5 and 6); however, statistical significance was 
not achieved. The large normal variation in those variables and the short study period of three 
days might have contributed to the lack of statistically significant findings of this study.  
It is known that toxins A and B are the main virulence factors of CDI; the 




studies (Davies et al., 2011; Chumbler et al., 2012). Toxin level detection through ELISA 
assays is commonly utilized as a diagnostic tool across different species; ELISA assays were 
performed on colonic contents collected at necropsy. The prevalence of pigs tested positive 
for the toxins was lower among piglets receiving NTCD prior challenge when compared to 
positive control piglets as well as challenged piglets that also received Lactobacillus sp. as 
probiotic.  Only 5.8% of the pigs from GROUP 5 tested positive while toxins were detected 
in approximately 30% of piglets from GROUPS 3, 4 and 6. 
Microscopic lesions observed within challenged pigs include loss of goblet cells, 
multifocal erosions and ulcerations which occasionally contain variable amounts of fibrin, 
necrotic debris and degenerate and non-degenerate neutrophils (volcano-like lesion). These 
microscopic findings are often observed in pigs with CDI. Diarrhea commonly observed is a 
result of decreased and/or impairment of colonic function.  
  Histopathologic examination is the most objective and accurate form to characterized 
and diagnose CDI in piglets. Yaeger et al. (2007) showed that constipation is commonly 
observed in CDI piglets and diarrhea is an inconsistent finding. Although toxin levels, 
mesocolonic edema and microscopic lesions were positively correlated on the present study; 
evaluation of field cases of CDI showed that a large proportion of healthy piglets (79%) were 
positive for C. difficile toxins (Yaeger et al., 2007).      
Combination of results achieved from statistical analysis of clinical scores, ELISA 
results and macroscopic and microscopic lesions suggests a benefit to the administration of 
NTCD as a competitive exclusions technique to prevent CDI in piglets. Data from this study 
does not support the use of a single administration of Lactobacillus sp. as an alternative to 




Multiple studies have investigated the efficacy of probiotic bacteria in the prevention 
of CDI; however, there still is great controversy among researchers. Recently, one meta-
analysis (McFarland, 2006) and two systemic reviews (Dendukuri et al., 2005; Pillai and 
Nelson, 2008) on this topic have shown enough evidence to support the benefit of using 
probiotics to prevent CDI in humans (Parkes et al., 2009). Probiotics in humans are 
administrated at multiple time points, as these bacteria often do not permanently colonize the 
intestines and will completely disappear in about 5-7 days (Mecenier et al., 2000). In this 
present study, the probiotic was administrated as a single dose at the beginning of the study. 
Our research group hypothesizes that this might have influenced the results obtained. The 
single administration was chosen based on the logistic challenges associated with multiple 
administrations of the product in a farm setting. Study pigs were manipulated individually 
and intragastrically administered with the probiotic product; this procedure was labor-
intensive and likely difficult to mimic on commercial farms due to large numbers of pigs and 
limited farm personal. Development of new equipment with self-feed capabilities to neonate 
pigs might allow the use of daily administration of probiotics. 
Single administration of NTDC did not produce side effects and was well tolerated by 
study piglets. Significant reduction in toxin levels, macroscopic and microscopic lesions 
were observed in piglets administered NTCD prior to challenge. Although the objective of 
this study was not to elucidate the mechanism by which NTDC prevents or reduces CDI; we 
hypothesis that competitive exclusion, where non-toxigenic strains will colonize the same 
niche of toxigenic strains and decrease the amount of bacterial colonization and consequently 
reduce disease. Other factors including competition for nutrients, modulation of immune 




Piglets are born with a virtually sterile intestinal tract. However colonization begins at 
parturition with different species of bacteria including C. difficile; Hopman et al showed that 
nearly one hundred percent of piglets acquire C. difficile within 48 hours-of-life (2011). Not 
all strains of C. difficile are toxigenic, strains lacking the toxin A and B genes are considered 
non-pathogenic. The true prevalence of pigs naturally colonized with NTCD has not yet been 
investigated. The prevalence of C. difficile carriage in humans is estimated to be between 4% 
and 7.6% where 42 to 50% of the isolates are non-toxigenic (Natarajan et al., 2013). 
Metagenomic studies investigating how the NTCD strain potentially modulates and alters the 
dynamic process of bacterial intestinal colonization in the neonate might shed light on the 
mechanism of protection conferred by this technique. 
Conclusion 
This study showed that the administration of NTCD decreased prevalence of toxin-
positive piglets, reduce mesocolonic edema and histopathologic lesions when compared to 
GROUPs 4 and 6 (C. difficile challenge piglets). Our research group believes that a treatment 
regime using only NTCD might not be the silver bullet veterinarians and producers have 
been looking for; however, a multicomponent approach involving good hygiene practices 
(decrease of exposure), decreased environmental stress and good management practices in 
conjunction with administration of a non-toxigenic strain of C. difficile may significantly 
prevent or ameliorate CDI in neonate piglets.  
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Tables and Figures 
Table 1. Experimental design for 1 day-old piglets administered with different bacterial 
probiotics and subsequent challenge with toxigenic C. difficile isolate ISU-15454-1, 
ribotype 078 
Group n* Treatment¶ Inoculation ɫ Challenge Dose 
1 10 - No - 
2 13 Non-toxigenic  
C. difficile spores @ 2 x10
6 No -  
3 14 Lactobacillus spp./Yogurt No - 
4 35 - Yes C. difficile spores @ 2 x106 
5 34 Non-toxigenic  
C. difficile spores @ 2 x10
6 Yes C. difficile spores @ 2 x10
6 
6 44 Lactobacillus spp./Yogurt Yes C. difficile spores @ 2 x106 
* Number of cesarean derived piglets per group.  
¶ Treatment was administered at 4 hours after parturition.  










Figure 1. Mesocolonic edema scores according to study groups including 1 day-old piglets 
administered with different bacterial probiotics and subsequent challenged with toxigenic C. 
difficile isolate ISU-15454-1, ribotype 078 
 
α GROUP 1 negative control, GROUP 2 non-toxigenic C. difficile (NTCD) only, GROUP 3 
Lactobacillus sp. only, GROUP 4 toxigenic C. difficile strain only, GROUP 5 NTCD and 
challenged with the toxigenic C. difficile strain, GROUP 6 Lactobacillus sp. and challenged 





Figure 2. Clostridium difficile toxin A/B ELISA scores of 1 day-old piglets (study animals 
were divided on 6 different groups 
α
) administered with different bacterial probiotics and 
subsequent challenge with toxigenic C. difficile isolate ISU-15454-1, ribotype 078.  
 
α GROUP 1 negative control, GROUP 2 non-toxigenic C. difficile (NTCD) only, GROUP 3 
Lactobacillus sp. only, GROUP 4 toxigenic C. difficile strain only, GROUP 5 NTCD and 
challenged with the toxigenic C. difficile strain, GROUP 6 Lactobacillus sp. and challenged 





Figure 3. Clostridium difficile histopathologic scores of 1 day-old piglets (study animals were 
divided on 6 different groups 
α
) administered with different bacterial probiotics and 
subsequent challenge with toxigenic C. difficile isolate ISU-15454-1, ribotype 078. 
 
α GROUP 1 negative control, GROUP 2 non-toxigenic C. difficile (NTCD) only, GROUP 3 
Lactobacillus sp. only, GROUP 4 toxigenic C. difficile strain only, GROUP 5 NTCD and 
challenged with the toxigenic C. difficile strain, GROUP 6 Lactobacillus sp. and challenged 
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Abstract 
Toxins A and B (TcdA and TcdB, respectively) are the major virulence factors associated 
with Clostridium difficile disease. Despite the international importance of the disease, there 
still exists a great deal of controversy regarding the role of TcdA and TcdB in the 
pathogenesis and immune response in vivo. Therefore, the objective of this pilot study was to 
develop a pig gut-loop ligation model to study the pathophysiology of TcdA and TcdB 
independently, and in combination, in segments of small intestine and colon. Eight, seven 
day-old conventionally-reared piglets were anesthetized and intestinal loops within jejunum, 
ileum and colon were surgically constructed. Each loop received either three ml of PBS 
(control), TcdA (204.8 ng/ml), TcdB (320 ng/ml) or combination of both toxins (102.4ng/ml 
and 160ng/ml, respectively). Results of this pilot study show histologic lesions were 
primarily localized within small intestine segments while colon segments were 
unremarkable. Once administrated, TcdA and TcdB simultaneously produced more severe 
histologic lesions when compared to individual toxin administration, suggesting a synergism 
between the two toxins. Additionally, TcdA exposure resulted in slightly higher 
histopathologic lesions when compared to TcdB alone. Relative gene expression including 




within intestinal loops; however, no association between toxin(s) exposure and expression 
was found.  We believe this model has the potential to contribute to investigations into 
pathogenesis of Clostridium difficile infection.  
Introduction 
Clostridium difficile, a Gram positive, anaerobic, spore-forming bacterium, is a major 
health concern for hospitalized patients. It is the most common pathogen associated with 
antibiotic-associated colitis and leading cause of infectious diarrhea in hospitals worldwide 
(Chumbler et al., 2012; Kelly and LaMont, 2008). Disease is not limited to humans and has 
been described in several other species including non-human primates, pigs, horses, primates, 
rabbits, rats, dogs and cats (Arroyo et al., 2005; Debast et al., 2009; Hopman et al., 2011; 
Keessen et al., 2011; Norman et al., 2009).  
Disruption of the gastrointestinal flora by antimicrobial usage is recognized as one of 
the most important risk factors of the disease (Lawley et al., 2009; Rupnik et al., 2009). 
Clinical signs associated with C. difficile infection (CDI) commonly include fever, severe 
abdominal pain and diarrhea; histopathologic examination of clinical cases often reveals 
pseudomembranous colitis. Recently, morbidity and mortality in humans from CDI has 
dramatically increased as a result of antibiotic usage patterns, an increase in community 
acquired infections and the emergence of specific strains that appear to be more virulent.  
(Carter et al., 2010). 
Despite the recent characterization of numerous surface layer proteins associated with 
CDI, it is well accepted that the toxins A and B are the major virulence factors associated 
with disease development (Borriello, 1998; Carter et al., 2010; Davies et al., 2011; Modi et 




ribosylating binary toxin; however, the role of this toxin in the pathogenesis of disease 
development has not yet been elucidated (Davies et al., 2011).  
Previous work in hamster suggested that TcdA alone can induce most of the clinical 
signs and pathology associated with CDI, and that TcdB was not toxic to animals unless 
TcdA was administered simultaneously (Lyerly et al., 1985; Voth and Ballard, 2005). 
However, recent studies and the appearance of the 027 ribotype strain have challenged this 
theory. The use of genetically modified strains of C. difficile via truncation and subsequent 
inactivation of particular toxin genes have allowed the investigation of each specific toxin`s 
role in hamster and in vitro tissue culture models. Results from these studies show that TcdB, 
not TcdA, is essential for disease development, and disruption of TcdB genes significantly 
reduced the virulence phenotype (Lyras et al., 2009). Clearly, the importance of TcdA and 
TcdB in disease pathogenesis is controversial and additional studies to better characterize the 
role of each toxin are warranted. 
The objective of this study was to develop a gut-loop ligation model using swine to 
study the pathophysiology of TcdA and TcdB independently and in combination in different 
segments of small intestine and colon. We believe that an understanding of the toxins` 
effects, the associated immunologic response, and intestinal gene expression are essential for 
the development of chemotherapeutics and vaccine development for the treatment and 
prevention of CDI.   
Materials and Methods 
Animals and experimental procedures   
 Eight conventionally-reared, Reproductive and Respiratory Syndrome Virus negative, 




2x2 m pen at a BSL-2 animal facility at Iowa State University (ISU) prior to the intestinal 
ligation surgery and fed a mixture of commercial puppy milk replacement (ESBILAC, 
Hampshire, IL) and yogurt (Great Value
®
, Walmart, Bentonville, AR) ad libitum. Piglets 
were fasted for 4 hours prior to surgery and rectal swabs were collected for toxin ELISA 
testing.   
            A pre-surgical dose of butorphanol (0.2-0.4 mg/kg IM) was administered prior to 
anesthetic induction. Piglets were mask induced with isoflurane followed by tracheal 
intubation and maintained with isoflurane during the procedure.  An IV catheter was placed 
after induction and piglets were positioned in dorsal recumbency for surgery. Following 
aseptic preparation of the surgical site, a subcutaneous infusion of lidocaine on the ventral 
midline was administered along with a dose of buprenorphine (0.01-0.02 mg/kg IM or IV) to 
minimize discomfort associated with the 8 cm laparotomy incision.  Three 15 cm segments 
of small intestine were exteriorized with approximately 10 cm loops constructed. Anatomical 
locations of the loops included 1) proximal jejunum 2) distal (aboral) jejunum and 3) ileum. 
Additionally, one loop of similar length from the centripetal coils of the ascending colon was 
exteriorized and ligated.  Three ml of solution containing either TcdA, TcdB, TcdA and 
TcdB or PBS were administrated intraluminally using a 25 gauge needle according to the 
experimental design (Table 1). Intestinal loop-construction and toxin administration are 
illustrated in Figure 1. The loops were then returned to the abdominal cavity.  The abdominal 
incision was routinely closed and piglets recovered uneventfully within approximately 20 
minutes. Postoperatively, piglets were individually housed in 18 gallon plastic totes 
(Rubbermaid
®
, Port Washington, NY) for 8 hours and monitored every 30 minutes for any 




collected and piglets were humanly euthanized by an intravenous overdose of pentobarbital. 
The experimental protocol was approved by the ISU Institutional Animal Care and Use 
Committee.  
C. difficile toxin A and Toxin B 
 Commercially available purified TcdA and TcdB (The Native Antigen Company, 
Oxfordshire, UK) were serially diluted in a PBS solution.  Dilutions were subsequently tested 
using a toxin-specific ELISA according to manufacturer’s recommendations (TechLab, 
Blacksburg, VA) to determine the approximate concentration of toxin equivalent to a 3+ 
result on a scale of 0 to 4+ (data not shown).  A 3+ result was selected due to the majority of 
C. difficile disease in piglets, where toxin can be detected, range from 2+ to 4+ on this test 
(ISU Veterinary Diagnostic Laboratory).  204.8 ng/ml of TcdA and 320 ng/ml of TcdB were 
administered in the designated loops according to experimental design (see Table 1.).  Loops 
administered both TcdA and TcdB received 102.4ng/ml and 160ng/ml, respectively. A total 
of 3 ml of PBS and toxin(s) was injected into each loop. 
Gene expression  
 At necropsy, approximately 5 cm segments of each intestinal ligated-loop were 
collected and serially sliced in sections of 0.5 cm and immediately placed on RNA collection 
buffer (RNAlater
®
, Life technologies, Carlsbad, CA) and frozen at -80 until RNA isolation 
was performed.  Approximately 150 mg of tissue was homogenized in 1.4 ml TriReagent 
(Life Technologies) in a M-tube using a GentleMACS™ dissociator (Miltenyi Biotec, San 
Diego, CA). RNA was extracted from 0.35 ml of the homogenate using the MagMAX™-96 
for Microarrays Total RNA Isolation Kit according to the manufacturer’s (Life 




with the spin isolation protocol. Following RNA extraction, cDNA was synthesized using 
SuperScript® VILO Master Mix according to manufacturer’s recommendations (Life 
Technologies). Real-time PCR was performed on a 7900 real-time instrument with 
TaqMan® primers and probe specific for swine mRNA targets with TaqMan® master mix 
(Life Technologies, Carlsbad, CA). Genes analyzed include: CASP1 –caspase 1; HAMP - 
Hepcidin antimicrobial peptide; ITGB2- integrin, beta 2 (complement component 3 receptor 
3 and 4 subunit); CSF3 - colony stimulating factor 3 (granulocyte); IL17A -interleukin 17A; 
IL1B - interleukin 1, beta; IL8 interleukin 8; NOS2 -  nitric oxide synthase 2, inducible; 
TLR4 - toll-like receptor 4; TNF alpha - tumor necrosis factor (TNF superfamily, member 2). 
All samples were run in duplicate and data analyzed using the 2-ddCt method (Livak and 
Schmittgen, 2001)   
Histopathologic examination  
Tissue sections were collected in 10% neutral buffered formalin and allowed to fix for at 
least 48 hr. Sections were then submitted for routine tissue sectioning followed by paraffin 
embedding, cutting (4 µm) and staining with hematoxylin and eosin. All tissues were 
examined by a veterinary pathologist (PA) blinded to piglet and section identification. Small 
and large intestinal sections were assessed and scored for goblet cell loss, neutrophilic 
aggregates within the lamina propria, and mucosal epithelial defects as previously described 
(Arruda et al., 2013; Lizer et al., 2012).  
Results 
Gene expression results 
For all intestinal samples collected, mRNA levels of BACT, CASP1, HAMP, ITGB2, 




is expressed as the fold change in gene expression in loops collected from toxin-treated 
piglets relative to anatomically similar loops from control pigs receiving PBS (Table 2).  
Results were calculated using the 2-ddCt method (Livak and Schmittgen, 2001) such that a 
value of 1 represents no change in expression,  a value > 1 represents the fold increase and a 
value < 1 represents a fold decrease relative to the same respective section from loops treated 
with PBS (control pigs). Relative gene expression from jejunal loops revealed an increase in 
mRNA expression of HAMP, IL17A and IL-8; however, these results were primarily 
associated with piglet C (TcdA and TcdB) and piglet E (TcdA). There was marked variation 
in gene expression levels between piglets.  
Results from ileal loops revealed a consistent increase in all genes from piglet E 
(TcdA) and piglet H (TcdB). Interestingly, gene expression from other challenged piglets 
was down regulated when compared to control piglets. Analysis from colon samples revealed 
a consistent down regulation of selected genes among challenged piglets. 
For the jejunal loops, each pig had one loop that was only administered PBS. Data 
analysis was performed for those piglets by the method described above (relative to control 
pigs in which PBS was administered in all loops). In addition, the data was analyzed as the 
relative gene expression of a toxin-administered jejunal loop compared to a PBS-
administered jejunal loop segment within the same piglet (Table 3).  Making comparisons 
within the same piglet showed there was a marked increase in the relative expression of 
HAMP, ITGB2, CSF3, IL17A, IL1B, IL8, NOS2, TLR4 and TNF in piglet C in which one 
loop received TcdA and TcdB and other loop received PBS.  These results are consistent 
when data was compared relative to loops from pigs that were given only PBS; though 





Microscopic examination of intestinal sections from control piglets (A and B) did not 
reveal significant lesions. Goblet cells were preserved throughout all the segments of small 
and large intestines and mucosal architecture was unremarkable. Lamina propria within 
proximal jejunum of piglet B was variably infiltrated by small aggregates of neutrophils. No 
other lesions were observed. Intestinal sections receiving both TcdA and TcdB (distal 
jejunum and ileum from piglets C and D) and TcdA alone had mild to moderate lesions 
predominately characterized by multifocal to locally extensive infiltration of neutrophils, 
which were often associated with scant amounts of cellular debris and goblet cell loss. The 
mucosa was occasionally disrupted and eroded; however, this change was not a predominant 
finding in the sections. Proximal jejunum sections from piglets C and D (PBS controls) were 
unremarkable; however, occasionally rare neutrophils were observed within lamina propria. 
Sections of proximal jejunum administrated TcdB were unremarkable; however, ileal 
sections from both piglets receiving TcdB showed mild lesions characterized by variably 
sized aggregates of neutrophils expanding the lamina propria and occasionally disrupting the 
epithelial architecture (exocytosis). No ulcerations or erosions were observed throughout 
examined sections.  
Histologic examination of large intestinal from all piglets did not reveal significant lesions. A 
detailed summary of histologic scores is presented in Table 4.  
Discussion 
Toxins A and B (TcdA and TcdB, respectively) are the major virulence factors associated 
with CDI; however, the exact mechanisms by which they elicit such gross and histologic 




and TcdB are part of the large clostridia glucosylating toxin family; they are very large toxins 
with molecular masses of 308 and 250 kDa, respectively.  Both TcdA and TcdB are 
internalized via receptor-mediated endocytosis. A decrease in the pH within the endosome 
compartment results in toxin conformation changes and pore formation allowing the release 
of the enzymatic domain of the toxin into the cytosol. Once within the cytosol of the cell, 
TcdA and TcdB target Rho GTPases which include Rho, Ras and Cdc42.  Inactivation of 
these cellular molecules disrupts cell signaling and compromises actin cytoskeleton 
regulation, which eventually leads to cell rounding and death (Chumbler et al., 2012; Davies 
et al., 2011; Dillon et al., 1995; Jank and Aktories, 2008; Just et al., 1994; Keel and Songer, 
2007).  
For over 30 years, animal models for C. difficile infection have undergone development 
and are currently being optimized (Best et al., 2012). Several different animals have been 
used as models to study CDI; some examples include hamster, mice, guinea pig, rat, prairie 
dogs, quails, rabbits and pigs (Best et al., 2012; Lawley and Young, 2013). The hamster 
model is the most well described and the most common animal model used to study CDI. 
Despite the characterization of this model, hamsters are exquisitely sensitive to the 
toxins’ effects (after antibiotic administration) and commonly die within a few days (Best et 
al., 2012; Keel and Songer, 2006). Rapid and uniformly fatal disease (Best et al., 2012; Keel 
and Songer, 2006; Lyerly et al., 1985) is not characteristic of CDI in humans. The rapid 
progression of disease in this species also poses obstacles when investigating possible 
treatments and/or preventive options.  
CDI is a naturally occurring disease in 1-7 days-old-piglets and considered one of the 




are moderately sensitive to the toxins’ effects and severity of clinical signs and histologic 
lesions can be altered by piglet-age and challenge dose (Steele et al., 2010). Additionally, the 
marked similarities in nature and progression of CDI in pigs to human disease (Best et al., 
2012; Steele et al., 2010) and the wide range of assays and immunoreagents commercially 
available make the pig model an attractive alternative to study the disease. 
The primary objective of this study was to develop an in vivo model to investigate the 
role of TcdA A and TcdB in and the immunologic-profile associated with CDI. Lesions 
associated with C. difficile infection are primarily found in the large intestine and rarely 
observed in the small intestine. For this study, intestinal-loops included three segments of 
small intestine and one segment of large intestine. Interestingly, the majority of lesions 
observed were localized in the small intestinal segments administrated TcdA and TcdB, and 
TcdA with large intestine segments being consistently unremarkable throughout all piglets.  
 The following three mechanisms might have influenced the lack of lesions within 
large intestine sections. First, we hypothesize that this finding may be due to the surgical 
protocol where, in order to preserve intestinal architectural integrity, intraluminal contents 
were left undisturbed. This might become relevant for toxin endocytosis as the contents 
within the small intestinal sections were liquid and markedly different when compared to the 
pasty-solid content within the colon. Direct contact and time-exposure between toxin and 
epithelium surface is likely necessary as these toxins are large molecules which are 
internalized via receptor-mediated endocytosis through the binding of the carboxy-terminal 





Low to no amount of toxin internalization might be associated with the lack of lesions 
on large intestine sections.  Second, purified toxin, not C. difficile spores or vegetative 
bacteria, were administered into intestinal loops. Perhaps the use of the spores or vegetative 
bacteria instead of purified toxin would yield more severe lesions. The first step of C. 
difficile infection likely consists of attachment and colonization of the intestines.  A previous 
study by Gomez-Trevino et al. showed that C. difficile is capable of attaching to different cell 
lines in vitro (Caco-2 and Vero cells) and in vivo (Gomez-Trevino et al., 1996). Colonization 
allows the bacteria to have direct contact with the cell surface as well as resist some innate 
immune mechanisms, such as peristaltic movements. It is known that surface layer proteins 
of the C. difficile wall are directly involved in adherence to mucus and epithelium cells 
(Calabi and Fairweather, 2002). Studies investigating the constituents of C. difficile cell wall 
have identified different surface layer proteins such as Cpw66 (Waligora et al., 2001), GroEL 
(Ternan et al., 2012), Fbp68 (Barketi-Klai et al., 2011; Hennequin et al., 2003), Cwp84 and 
the presence of flagella (Tasteyre et al., 2001). In summary, studies have shown that these 
different proteins are directly related to bacterial colonization and indirectly related to toxin 
binding and internalization.  
It is a consensus among the medical community that disruption of the microbiota is 
the major risk factor associated with CDI. Microbial population and diversity increases 
gradually when moving from stomach to small intestines to colon where bacteria densities 
can reach as high as  10
12
 per grams of content (Rossi et al., 2013). Studies evaluating the 
impact of the microbial flora have shown that these normal bacterial residents can impact C. 
difficile colonization and in some circumstances toxin binding (Fitzpatrick, 2013; Hell et al., 




boulardii can inhibit TcdA receptor binding through the release of proteases that digest both 
the toxin as well as the TcdA cellular receptors (Castagliuolo et al., 1996; Pothoulakis et al., 
1993; Pothoulakis, 2009). The impact of the loop formation on the intestinal resident 
microflora was not evaluated in this study and could have played a role in toxin binding, 
internalization and may be associated with the lack of lesions within the colon segments.  
Small intestinal segments administrated both TcdA and TcdB concurrently had higher 
histologic scores followed by segments receiving only TcdA. Our results are consistent with 
previous studies suggesting the synergistic effects of these toxins (Du and Alfa, 2004; Kim et 
al., 1987; Lyerly et al., 1985; Voth and Ballard, 2005). However, TcdA alone resulted in 
higher histologic scores when compared to TcdB only, which is inconsistent with the most 
recent literature that states that TcdB is significantly more toxigenic than TcdA (Lyras et al., 
2009; Riegler et al., 1995).  This discord may be due to the duration of this present study 
which may have resulted in insufficient time to develop pathology associated with TcdB. He 
and others (He et al., 2002) have shown that TcdA localizes in the mitochondria as early as 5 
to 10 minutes after cell-membrane binding resulting in increased reactive oxygen 
intermediates, decreased ATP production, release of cytochrome C and activation of the NF-
kB pathway that ultimately induces cytokine production (such as IL-8). Release of 
cytochrome C is associated with initiation of apoptosis (Cai and Jones, 1998; Petit et al., 
1996; Susin et al., 1999). Although a majority of cell damage and histologic lesions 
associated with C. difficile are attributed to the glucosylation and inactivation of the GTPases 
of the Rho family and subsequent cytoskeleton damage, the previous study has shown 
mitochondrial damage with activation of NF-kB and IL-8 production occurs independently 




and monocyte cell line, occurs approximately 15 minutes after TcdA has reached the 
mitochondria and prior to glucosylation of GTPases protein on the cell. Little is known about 
the time required to elicit the pathologic effects of TcdB.  Accordingly, increasing the 
duration of the study, and therefore the amount of time TcdB is associated with the intestinal 
epithelium, may be necessary to fully evaluate the effects of TcdB.  In addition, slight 
modifications to the surgical protocol such as removal of intestinal contents prior to 
inoculum administration along with the longer TcdB period exposure might be beneficial for 
future studies. 
Genes evaluated in this study were selected based on the clinical signs and histologic 
lesions observed with CDI. Comparison in gene expression from jejunum loops of control 
and challenged piglets revealed an increase of mRNA levels of HAMP, IL17A, IL-1β, IL-8, 
NOS2 and TLR4 in piglet C (TcdA and TcdB).  Upregulation of these genes was associated 
with a high histologic score (Figure 2). Histologic examination of the jejunum revealed a 
moderate to marked neutrophilic infiltration and multifocal goblet cell loss. Evaluation of 
gene expression between ileum loops from control and challenged piglets revealed a 
consistent upregulation across examined genes for piglets E (Tcd A) and H (Tcd B). These 
results are in agreement with histologic scores where moderate to marked neutrophilic 
infiltration was observed. Interestingly, gene expression from other challenged piglets was 
slightly down regulated when compared to control piglets; we hypothesized these results 
might be within normal individual variation and large sample sizes are likely necessary to 
detect any numerical or statistical difference. Analysis from colon samples revealed a 




agreement with histologic findings where no significant histopathologic lesions were 
observed. 
A second method of comparison was performed between different jejunum loops 
within each piglet. Results from piglet C, where one loop received TcdA and TcdB and 
another loop which received PBS showed a marked increase of expression of the following 
genes HAMP, ITGB2, CSF3, IL17A, IL1B, IL8, NOS2, TLR4 and TNF. This result is 
reflected by the high histologic score observed in jejunum sections administrated TcdA and 
TcdB when compared with sections receiving PBS. 
The main objective of gene expression evaluation was to demonstrate the capability 
and usefulness of such techniques when investigating the pathophysiology of an infectious 
disease and the associated inflammatory response; in this case with C. difficile infection. 
Within this study, there were several occasions in which gene expression results were not 
associated with histologic scores.  This difference could be for several reasons. First, a very 
small portion of the intestine was used for RNA extraction and it’s possible the cells in that 
microenvironment were subject to different levels of toxin. Second, we used the entire 
intestinal section in our analysis as opposed to a mucosal scraping. There may have been an 
abundance of RNA from cells not affected by the toxin that diluted the changes in affected 
cells. Future studies would aim to address these differences to further develop the model.  
Conclusions  
In summary, our results demonstrate that the porcine intestinal loop model has the 
potential to become a valuable and repeatable resource to further investigate the 
pathophysiology and associated inflammatory response associated with individual 




preliminary data it appears that the TcdA and TcdB, when administered simultaneously, are 
more toxigenic and capable of inducing a more severe inflammatory response.     
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Tables and Figures 
Table 1. Experimental design. Intestinal loop segments were named according to anatomical 
location of loop. Jejunum 1 and Jejunum 2 correspond to proximal and distal portions of the 
jejunum, respectively. One segment of ileum and colon was constructed per piglet. Individual 
loops received assigned treatment. Piglets A and B were considered negative controls as no 













Phosphate buffered saline was used as negative control. 
†
 C. difficile toxin A, total of 3 ml of 204.8 ng/ml solution was administered/loop. 
‡
 C. difficile toxin B, total of 3 ml of 320 ng/ml solution was administered/loop. 
Π




Jejunum 1 Jejunum 2 Ileum Colon 
A . PBS
*
. PBS PBS 
B . PBS. PBS PBS 
C PBS A&B 
π
 A&B A&B 
D PBS A&B A&B A&B 
E A
†
 PBS A A&B 
F A PBS A A&B 
G B
‡
 PBS B B 




Table 2. Analysis of relative gene expression quantified using Real-Time Quantitative PCR 
and the 22
-ΔΔC
T. Values shown are the relative gene expression of collected loops from 
challenged piglets compared to anatomically similar loops from control piglets receiving 
PBS. Value =1 represents no change, value >1 for a fold increase, and value <1 for fold 
decrease in expression relative to piglets A and B (negative control piglets with PBS treated 
loops). 
Jejunum* 
Pig ID CASP1 HAMP ITGB2 GCSF IL17A IL1β IL8 NOS2 TLR4 TNFα 
C 0.95 5.65 1.44 1.24 5.90 2.00 2.64 1.84 1.93 1.40 
D 0.76 2.03 1.21 1.09 0.16 0.27 0.16 0.89 0.70 1.04 
E 1.10 14.27 0.44 1.39 3.44 1.06 3.01 1.36 1.24 0.41 
F 2.75 0.47 0.69 1.14 1.71 0.98 0.48 0.77 2.58 0.30 
G 1.39 0.25 0.32 0.31 0.21 0.30 1.00 0.40 1.07 0.43 
H 3.34 0.14 0.49 0.54 0.42 0.45 0.75 0.38 1.69 0.38 
Ileum 
Pig ID CASP1 HAMP ITGB2 GCSF IL17A IL1 β IL8 NOS2 TLR4 TNFα 
C 0.75 0.24 1.00 0.88 0.77 0.39 0.42 0.52 0.85 0.82 
D 1.50 1.00 1.03 0.92 0.50 2.70 0.48 1.34 0.97 1.12 
E 1.40 4.76 1.10 1.67 11.35 3.32 3.77 2.41 2.22 1.88 
F 1.58 0.25 1.11 1.43 1.17 0.15 0.09 0.95 0.53 0.68 
G 1.70 0.96 0.79 0.36 0.48 0.91 1.83 0.95 1.13 0.95 
H 1.75 1.90 1.48 1.22 2.84 5.96 2.12 2.57 1.83 1.84 
Colon 
Pig ID CASP1 HAMP ITGB2 GCSF IL17A IL1 β IL8 NOS2 TLR4 TNFα 
C 0.53 0.68 0.35 0.63 1.80 0.52 1.11 0.39 0.74 0.32 
D 0.49 0.62 0.32 0.50 0.55 0.22 0.39 0.94 0.20 0.24 
E 0.77 1.20 0.31 0.41 1.11 0.17 0.81 1.05 0.22 0.33 
F 0.50 4.36 0.36 0.71 1.27 0.46 1.73 0.42 0.39 0.24 
G 0.57 0.28 0.33 0.39 0.72 0.27 0.97 1.15 0.34 0.38 
CASP1 –caspase 1; HAMP - Hepcidin antimicrobial peptide; ITGB2- integrin, beta 2 
(complement component 3 receptor 3 and 4 subunit); CSF3 - colony stimulating factor 3 
(granulocyte); IL17A -interleukin 17A; IL1B - interleukin 1, beta; IL8 interleukin 8; NOS2 -  
nitric oxide synthase 2, inducible; TLR4 - toll-like receptor 4; TNF - tumor necrosis factor 
(TNF superfamily, member 2). 
*Jejunum segments administrated with toxin A and/or toxin B. Jejunum segments 




Table 3. Analysis of relative gene expression quantified using Real-Time Quantitative PCR 
and the 2
-ΔΔC
t. Values shown are the relative gene expression of jejunum loop administered 
toxin compared to jejunum loop segment from same piglet administered PBS. Value =1 
represents no change, value >1 for a fold increase, and value <1 for fold decrease in 
expression relative to that piglet’s PBS treated loop. 
Pig ID CASP1 HAMP ITGB2 GCSF IL17A IL1B IL8 NOS2 TLR4 TNFA 
C 0.50 40.49 3.74 1.94 10.14 9.68 5.18 10.56 2.43 5.04 
D 0.25 0.30 3.18 0.83 0.20 0.37 0.16 0.62 0.86 1.96 
E 0.83 6.21 1.08 1.35 6.20 2.27 1.83 1.98 0.95 1.04 
F 2.22 0.39 0.42 0.76 1.85 2.14 2.28 0.61 2.10 0.24 
G 1.21 0.61 0.71 0.91 0.90 0.93 0.86 0.66 1.68 0.86 
H 1.96 0.09 0.38 1.18 0.21 0.10 0.24 0.25 0.54 0.20 
CASP1 –caspase 1; HAMP - Hepcidin antimicrobial peptide; ITGB2- integrin, beta 2 
(complement component 3 receptor 3 and 4 subunit); CSF3 - colony stimulating factor 3 
(granulocyte); IL17A -interleukin 17A; IL1B - interleukin 1, beta; IL8 interleukin 8; NOS2 -  
nitric oxide synthase 2, inducible; TLR4 - toll-like receptor 4; TNF - tumor necrosis factor 




























A . . . 0 0 0 0 0 0 0 0 0 
B . . . 0 2 0 0 0 0 0 0 0 
C 0 0 0 2 3 1 1 2 1 0 0 0 
D 0 1 0 2 3 1 1 2 0 0 0 0 
E 0 1 0 0 1 0 1 3 0 0 0 0 
F 2 3 1 0 3 0 0 0 0 0 0 0 
G 0 0 0 0 0 0 0 1 0 0 0 0 
H 0 0 0 0 0 0 0 2 0 0 0 0 
*












Figure 1. Surgical construction of intestinal loops on 7 day-old anesthetized piglets and intraluminal administration of C. difficile 
TcdA and TcdB.  
 
1a. Construction of loop from proximal jejunum. Loops measure approximately 10 cm in length; 1b. construction of loop from 
centripetal segment of ascending colon; 1c. administration of 3 ml of solution containing either PBS or TcdA and/or  TcdB in PBS 




CHAPTER 5.  GENERAL CONCLUSIONS 
The number of human cases of antibiotic-associated diarrhea (AAD) has increased 
since the 1950’s, which corresponds with the beginning of the antibiotic-era. However, 
Clostridium. difficile was not classified as a pathogen until the late 1970’s when a small 
cohort of patients suffering from AAD was identified based on a common clindamycin 
administration history (Bartlett J. G. et al., 1977; Tedesco F. J. et al., 1974). The bacterium 
has become the leading cause of infectious diarrhea in developed countries and the primary 
cause of AAD worldwide (Bartlett J. G. 2002; Carter G. P. et al., 2010; Keel M. K., Songer, 
J. G., 2006; Kelly C. P., LaMont, J. T. 2008; McDonald L. C. et al., 2005; Steele J. et al., 
2010). The disease is estimated to cost approximately € 3 billion per year in the European 
Union and between $436million to $3.2 billion annually in the United States.   
Clostridium difficile is a Gram positive, anaerobic, spore-forming bacterium 
commonly found in the environment including soil, water, vegetables (al S. N., Brazier, J. S., 
1996), and the gastrointestinal tract of animals (Songer J. G., 1996). Clostridium difficile 
produces metabolically-dormant spores which are directly linked with environmental 
survival and consequently associated with transmission, epidemiology and pathogenesis of 
AAD. Clostridium difficile spores are highly resistant to oxygen exposure, desiccation, and 
most common disinfectants, surviving for months and probably years in the environment 
(Wullt M. et al., 2003). Toxins A and B produced by vegetative bacteria are the major 
virulence factors; however, the exact mechanisms and the role and importance of each toxin 
are yet to be fully elucidated. 
The disease in humans is often associated with events of intestinal microbiota 




domestic animals; however, immature intestinal flora commonly observed in neonatal 
animals is also considered a major risk factor to C. difficile infection. Human treatment is 
directed at the reestablishment of the intestinal microbiota by interruption of antibiotic 
treatment, usage of a probiotic, fecal transplant (Vaishnavi C., 2014) and the use of selective 
antibiotics. Currently, there is no approved vaccine or antibody therapy available.  
Clostridium difficile infection has also been described in several non-human species 
including pigs, horses, primates, rabbits, rats, dogs and cats (Arroyo L. G. et al., 2005; 
Debast S. B. et al., 2009; Hopman N. E. et al., 2011; Keessen E. C. et al., 2011a; Norman K. 
N. et al., 2009). In piglets, CDI often occurs in the first week-of-life. Studies have shown that 
C. difficile intestinal colonization occurs within the first hours of life in the neonatal pig, and 
nearly all piglets in some herds are colonized within 48 hours of birth (Hopman N. E. et al., 
2011). Despite the endemic nature of bacteria, not all piglets develop disease. Reports on 
affected herds showed that on average 66% of the litters are affected, and within affected 
litters the morbidity can reach 97 to 100% (Anderson M. A., Songer, J. G., 2008; Songer J. 
G., 2004). Mortality is highly depended on factors including management and concurrent 
infectious etiologies. Some studies have reported mortality rates as high as 16% (Anderson 
M. A., Songer, J. G., 2008). Piglets often showed growth retardation with lower weaning 
weights averaging a half a kilogram less when compared to unaffected littermates (Songer J. 
G., 2004). Despite the economic and welfare concerns associate with CDI in piglets, there is 
a significant lack of knowledge regarding risk factors, pathogenesis and treatment options for 
CDI in piglets. 
This thesis documents our efforts to increase the understanding of risk factors, 




primarily objective to investigate three potential risk factors associated with CDI in piglets; 
to our knowledge these were the first studies to investigate the impact of bacterial dosage, 
piglet age and antimicrobial treatments on the development of disease. First, we 
demonstrated that the C. difficile isolate (isolate 15454-1, ribotype 078, toxinotype V) used in 
this study was able to cause C. difficile disease in piglets with development of typical gross 
and histologic lesions. Results evaluating the role of antibiotic administration as a potential 
risk factor revealed that the usage of Lincomycin, Ceftiofur, Tylosin or Tulathromycin prior 
to C. difficile challenge did not increase the prevalence of disease or enhance of lesions 
severity. 
We believe that these results can be explained by the fact that one day-old piglets do 
not have an established intestinal microflora, and therefore antibiotics would not significantly 
alter the microbiota. Future studies investigating bacterial colonization, succession and 
competition in the first day-of-life may provide a better understanding of the impact of 
antibiotic administration on the colonic microbiota.  
It is known that the vast majority of CDI cases occur in piglets within the first week-
of-life; however, studies investigating the susceptibility of older (10-days-old), commercial 
piglets to CDI have not been published. Results from this study showed that older piglets are 
as susceptible to CDI as neonate piglets. However, extrapolation from these results should 
not be directly applied to field cases as these piglets were raised in a controlled environment 
considerably different than a commercial farm. Although, these results do demonstrated that 
10-days-old piglets have receptors for toxins A and B and, in special circumstances, can 
develop CDI. Additionally, C. difficile dosage was identified as an important risk factor 




increase of prevalence and severity of microscopic lesions typical of CDI. Therefore, good 
management practices that decrease the exposure of neonatal piglets to a high challenge dose 
and allow the establishment of a healthy microflora is likely essential to prevent of CDI in 
piglets.  While antibiotic usage is the most important risk factor for other species, it does not 
appear to be significantly important in piglets.  
Regarding the prevention and control of CDI in piglets; to our knowledge this was the 
first experiment, under controlled settings, designed to evaluate the benefits of a non-
toxigenic C. difficile strain and Lactobacillus sp. as probiotics in the prevention of CDI in 
piglets. Results from this study showed that the use of non-toxigenic C. difficile (NTCD) as a 
probiotic may be beneficial; piglets that received NTCD prior to challenge with a toxigenic 
strain had a decreased prevalence of toxin-positive piglets, less mesocolonic edema and 
lower histopathologic scores. The use of a single administration of Lactobacillus sp. as a 
probiotic was not beneficial in the prevention of CDI in piglets in this particular study. Future 
studies investigating the prevalence of NTCD among commercial piglets as well as 
experiments investigating the impact of NTCD strains on bacterial intestinal colonization in 
the neonate will likely advance our understanding of the mechanism of protection conferred 
by the use of NTCD as a probiotic.  
Chapter 4 of this dissertation described a pilot study in which a pig intestinal-loop 
ligation model was developed providing an alternative in vivo model to investigate the role of 
toxins A and B and the cytokine-profile associated with CDI in different segments of the 
small intestine and colon. In additional to histopathologic characterization of lesions, 
expression of selected genes was also evaluated. Results from this study showed a potential 




histologic scores when compared to individual toxins. These results are in agreement with 
previous C. difficile pathogenesis studies (Du T., Alfa, M. J., 2004; Kim P. H. et al., 1987; 
Lyerly D. M. et al., 1985; Voth D. E., Ballard, J. D., 2005).  Interestingly, toxin A 
administration led to higher histologic scores when compared to toxin B in this particular 
study. These latter results are inconsistent with the most recent literature that states that toxin 
B is significantly more toxigenic than toxin A (Lyras D. et al., 2009; Riegler M. et al., 1995). 
Genes were upregulated in segments receiving both toxin A and B; however, this finding was 
inconsistent and not routinely associated with histologic lesions. Surprisingly, a majority of 
lesions were observed within small intestinal sections while colon was often unremarkable 
across treatment groups.  
When optimized this in vivo model has the potential to become a valuable resource, 
providing a novel and appropriate manner by which to investigate the pathogenic 
mechanisms of toxins A and B, the associated immunologic response, and intestinal gene 
expression. We believe that such insight is essential for the development of new antibiotics 
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